https://trial.medpath.com/news/76f0acd4958bf89f/oric-pharmaceuticals-gains-36-following-positive-cancer-data-and-strategic-partnerships 2026-01-27T03:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/46c8430f822c2c69/argo-biopharma-s-sirna-therapeutic-bw-20829-enters-phase-2b-trial-for-elevated-lipoprotein-a-and-cardiovascular-disease 2026-01-27T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/19abc5f8c4c4ba88/fda-accepts-first-quality-control-protocol-for-mesenchymal-stromal-cells-setting-new-therapeutic-standard 2026-01-27T03:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/b18a5c902512d581/lower-dose-venetoclax-shows-promise-for-chinese-patients-with-hematological-malignancies 2026-01-26T03:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/859f599d2a95fa6f/avita-medical-demonstrates-first-integrated-use-of-three-advanced-wound-care-technologies-at-boswick-symposium 2026-01-26T03:09:35+00:00 hourly 0.9 https://trial.medpath.com/news/b035590e631aba96/philippines-fda-advances-green-lane-initiative-to-fast-track-local-pharmaceutical-manufacturing-approvals 2026-01-26T03:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/79e33e9a30170557/targeting-oxldl-shows-promise-for-enhancing-pd-1-immunotherapy-in-osteosarcoma 2026-01-26T03:07:37+00:00 hourly 0.9 https://trial.medpath.com/news/f4835e21327e2614/uk-life-sciences-companies-drive-ps3-7-billion-revenue-growth-in-sunday-times-tech-100 2026-01-26T03:00:21+00:00 hourly 0.9 https://trial.medpath.com/news/eda53c6a77eba1d1/avanos-medical-and-siemens-healthineers-form-strategic-partnership-to-advance-outpatient-pain-management-technologies 2026-01-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/086e39f943bec4a0/novo-medi-sciences-launches-nexipox-plus-varicella-vaccine-with-enhanced-stability-technology-for-indian-market 2026-01-25T13:47:14+00:00 hourly 0.9 https://trial.medpath.com/news/4dac69be683bcab3/blinatumomab-linked-to-increased-epstein-barr-virus-reactivation-in-pre-transplant-patients 2026-01-25T13:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/41e9251927341f74/cabaletta-bio-receives-fda-clearance-for-automated-car-t-manufacturing-platform 2026-01-25T13:44:18+00:00 hourly 0.9 https://trial.medpath.com/news/05d7f7a79eb3a4bb/nextcure-advances-two-adc-programs-with-q2-2026-data-readout-expected-for-cdh6-targeted-therapy 2026-01-25T13:35:43+00:00 hourly 0.9 https://trial.medpath.com/news/601b4de00cb89f8d/cipla-faces-major-production-crisis-as-cancer-drug-manufacturing-halt-drives-57-profit-decline 2026-01-24T18:06:16+00:00 hourly 0.9 https://trial.medpath.com/news/e8e7a0ab7e05f7a9/novartis-expands-rna-interference-portfolio-as-next-strategic-platform-following-radioligand-and-car-t-success 2026-01-24T18:05:41+00:00 hourly 0.9 https://trial.medpath.com/news/3ff3f4ea9548ac75/axion-biosystems-acquires-cytotronics-high-density-cmos-mea-technology-to-advance-drug-discovery 2026-01-24T18:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/c2b49e19590fb318/onesource-specialty-pharma-reports-26-revenue-decline-as-semaglutide-approval-delays-hit-q3-performance 2026-01-24T18:00:59+00:00 hourly 0.9 https://trial.medpath.com/news/cb9750c34f1d0481/bioage-labs-raises-115-million-in-upsized-public-offering-to-advance-metabolic-disease-pipeline 2026-01-24T04:39:04+00:00 hourly 0.9 https://trial.medpath.com/news/225d205db0209719/immunis-reports-first-phase-2-data-for-secretome-based-biologic-showing-26-improvement-in-gait-speed-in-obese-seniors 2026-01-24T00:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/c30889aefccdb2c1/intuitive-surgical-receives-fda-clearance-for-da-vinci-5-robot-in-cardiac-procedures 2026-01-24T00:39:32+00:00 hourly 0.9 https://trial.medpath.com/news/8b3463cc2f32b7de/nih-s-recover-tlc-long-covid-trials-face-delays-won-t-begin-enrollment-until-summer-2026 2026-01-24T00:38:58+00:00 hourly 0.9 https://trial.medpath.com/news/7aa2edf7d1b6ce69/telyrx-digital-pharmacy-platform-goes-public-through-40-million-spac-transaction 2026-01-23T20:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/b76858af51be6665/philip-morris-international-seeks-fda-authorization-for-zyn-as-modified-risk-tobacco-product 2026-01-23T20:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/0c71e6e83147a47a/bausch-health-s-red-c-phase-3-trial-fails-to-meet-primary-endpoint-in-hepatic-encephalopathy-prevention 2026-01-23T20:31:37+00:00 hourly 0.9 https://trial.medpath.com/news/2c2acf14d53a5823/belimumab-demonstrates-sustained-long-term-benefits-for-cutaneous-lupus-in-real-world-study 2026-01-23T20:30:43+00:00 hourly 0.9 https://trial.medpath.com/news/6828e8faeb4c7410/crispr-study-identifies-two-genes-as-predictive-biomarkers-for-cancer-immunotherapy-response 2026-01-23T20:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/1e69f4debfe4600f/privo-technologies-prv211-intraoperative-chemotherapy-patch-meets-primary-safety-endpoint-in-head-and-neck-cancer-trial 2026-01-23T20:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/c98e17c1a11da55b/blau-farmaceutica-achieves-historic-milestone-with-first-brazilian-developed-pembrolizumab-biosimilar 2026-01-23T20:29:32+00:00 hourly 0.9 https://trial.medpath.com/news/09de42e6d471cd2a/naprod-life-sciences-secures-anvisa-gmp-certification-renewal-for-oncology-manufacturing-operations 2026-01-23T20:29:27+00:00 hourly 0.9 https://trial.medpath.com/news/b10d724ffc8bb76f/high-dose-subcutaneous-biologics-set-to-transform-drug-delivery-as-industry-shifts-from-iv-administration 2026-01-23T20:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/60172c22674d2b9f/atley-solutions-and-perceptive-discovery-form-strategic-partnership-to-advance-astatine-211-radiopharmaceutical-development 2026-01-23T20:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/ee095422e9c61f3b/cd137-targeted-therapies-advance-with-90-clinical-trials-spanning-multiple-cancer-types 2026-01-23T20:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/9d049e49f67627ba/sinovac-secures-exclusive-hepatitis-a-vaccine-contract-in-oman-breaking-into-gcc-market 2026-01-23T20:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/5463eff8ac982f4e/glp-1-receptor-agonists-outperform-traditional-diabetes-treatments-in-large-comparative-study 2026-01-23T16:15:47+00:00 hourly 0.9 https://trial.medpath.com/news/5071fc37a35b2c30/astrazeneca-secures-court-injunction-blocking-generic-diabetes-drug-launch-in-australia 2026-01-23T16:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/4b235401339c3a48/china-approves-first-in-class-monoclonal-antibody-for-chronic-hepatitis-d-treatment 2026-01-23T16:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/9d5a53ae251826b7/doubling-dolutegravir-dosage-reduces-hiv-viral-reservoir-in-suppressed-patients 2026-01-23T16:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/6af4605a3a665dbb/personalized-t-cell-activator-itac-xs15-cll01-demonstrates-safety-and-immunogenicity-in-phase-1-chronic-lymphocytic-leukemia-trial 2026-01-23T16:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/6ef5f453770ae2b5/choroideremia-research-foundation-acquires-spark-therapeutics-gene-therapy-assets-to-advance-rare-disease-treatment 2026-01-23T16:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/4f2459606b9b219f/curative-biotechnology-secures-canadian-patent-for-novel-retinal-degeneration-target 2026-01-23T16:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/65d08200f933bee3/akums-secures-eu-gmp-certifications-for-two-haridwar-manufacturing-plants-expanding-european-market-access 2026-01-23T16:13:11+00:00 hourly 0.9 https://trial.medpath.com/news/d571f207c376ddfd/bausch-health-s-phase-3-red-c-trials-for-hepatic-encephalopathy-prevention-fail-to-meet-primary-endpoint 2026-01-23T16:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/cfe58ccf2deb38fb/musc-researchers-develop-novel-antibody-targeting-sfrp2-to-combat-triple-negative-breast-cancer-resistance 2026-01-23T12:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/4f2ac2ebfe7455cc/car-t-cell-therapy-targets-tumor-macrophages-to-overcome-immunotherapy-resistance-in-metastatic-cancer 2026-01-23T04:50:56+00:00 hourly 0.9 https://trial.medpath.com/news/2650d0d80b924fa0/medtronic-partners-with-university-of-colorado-to-accelerate-healthcare-innovation-in-ai-robotics-and-sustainability 2026-01-23T04:50:40+00:00 hourly 0.9 https://trial.medpath.com/news/9b5a4a561f748e2b/moderna-halts-new-vaccine-trial-investments-amid-us-policy-opposition 2026-01-23T00:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/b6ff6ca213039348/indian-patent-office-rejects-abbvie-s-venetoclax-patent-application-opening-door-for-generic-competition 2026-01-23T00:33:13+00:00 hourly 0.9 https://trial.medpath.com/news/44eb1fb66abe1463/concept-medical-initiates-global-stars-dapt-trial-for-polymer-free-drug-eluting-stent-in-stemi-patients 2026-01-23T00:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/43495c1a34878a82/mitocarex-bio-reports-positive-in-vitro-results-for-novel-mitochondrial-carrier-targeting-anti-inflammatory-compounds 2026-01-23T00:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/cea95fcf3f4466ad/biocryst-completes-700-million-acquisition-of-astria-therapeutics-to-strengthen-hereditary-angioedema-leadership 2026-01-23T00:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/218767c16c4ebb7c/florida-cancer-specialists-launches-phase-3-trial-of-pasritamig-bispecific-t-cell-engager-for-castration-resistant-prostate-cancer 2026-01-23T00:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/61caaa8b4d5d2869/ellipses-in-licenses-first-in-class-b7h3-antibody-drug-conjugate-from-innolake-biopharm 2026-01-23T00:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/01e178cb73302c5d/uk-regulatory-agency-removes-two-prescriber-requirement-for-isotretinoin-in-under-18-patients 2026-01-23T00:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/bed51f526937485a/ruxolitinib-combination-therapy-shows-promise-in-checkpoint-inhibitor-resistant-hodgkin-lymphoma 2026-01-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e05270416bd4863/phasev-unveils-ai-powered-platform-to-accelerate-ibd-clinical-trials-through-predictive-site-selection 2026-01-22T20:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/e36f71d0359f0320/spotitearly-partners-with-fox-chase-cancer-center-to-validate-ai-canine-breath-based-cancer-detection-technology 2026-01-22T20:04:27+00:00 hourly 0.9 https://trial.medpath.com/news/2369eab23ed19239/60-degrees-pharmaceuticals-partners-with-runway-health-to-expand-arakoda-access-for-malaria-prevention 2026-01-22T20:04:26+00:00 hourly 0.9 https://trial.medpath.com/news/2a473896ff7359b3/ace-inhibitors-show-significant-mortality-reduction-in-idiopathic-pulmonary-fibrosis-patients 2026-01-22T16:26:32+00:00 hourly 0.9 https://trial.medpath.com/news/8804cb22b0e78b83/abatacept-shows-long-term-benefits-in-delaying-rheumatoid-arthritis-onset-by-up-to-four-years 2026-01-22T16:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/d2ac5ec97f11135f/fda-expands-digital-health-deregulation-with-revised-guidance-on-wearables-and-clinical-decision-support-software 2026-01-22T16:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/77be3963f4a9d4ae/fda-considers-approving-reduced-risk-marketing-claims-for-zyn-nicotine-pouches 2026-01-22T16:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/58e7c27292622e8b/hoth-therapeutics-reports-100-response-rate-in-cancer-trial-reducing-disease-severity-by-half 2026-01-22T16:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/1f4effe4df5ace3d/paq-therapeutics-initiates-first-in-human-trial-of-pan-kras-degrader-pt0511-secures-77-million-in-series-b-funding 2026-01-22T16:23:53+00:00 hourly 0.9 https://trial.medpath.com/news/f4fa88f74d7158f2/bristol-myers-squibb-partners-with-janux-therapeutics-in-850m-tumor-activated-cancer-drug-deal 2026-01-22T16:23:51+00:00 hourly 0.9 https://trial.medpath.com/news/3ad54e60ff3941ee/biomerieux-acquires-accellix-for-eur35m-to-strengthen-cell-and-gene-therapy-quality-control-portfolio 2026-01-22T16:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/64d1525e3505f098/mendra-raises-82-million-series-a-to-transform-rare-disease-development-through-ai-driven-strategy 2026-01-22T16:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/8a56f134e5aae342/voyager-technologies-partners-with-space-liintech-for-iss-based-protein-crystallization-research 2026-01-22T16:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/b8d8837dd7b87a0e/curant-rare-and-cencora-form-strategic-partnership-to-streamline-rare-disease-therapy-commercialization 2026-01-22T16:23:23+00:00 hourly 0.9 https://trial.medpath.com/news/3e81c8466a277aaf/walmart-launches-clinical-research-sites-in-former-health-clinics-to-expand-trial-access-in-underserved-communities 2026-01-22T16:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/f680b903a5bc0b7e/human-continuum-appoints-dr-omar-khalid-sial-as-chief-scientific-officer-to-advance-exosome-based-therapeutics-platform 2026-01-22T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/52bec00195515daa/india-cuts-drug-trial-manufacturing-review-timeline-in-half-to-accelerate-pharmaceutical-development 2026-01-22T12:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/8220aeb61c65290e/nerlynx-launches-in-thailand-as-new-her2-breast-cancer-treatment-option 2026-01-22T12:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/44fbe364318728e8/caverstim-implantable-neurostimulator-shows-promise-in-first-in-man-study-for-post-prostatectomy-erectile-dysfunction 2026-01-22T12:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/54a15ef2f34a3af5/pulsesight-therapeutics-completes-phase-i-dosing-for-novel-gene-therapy-pst-611-in-geographic-atrophy 2026-01-22T12:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/aa5c8bd909d76771/azafaros-to-present-phase-3-nizubaglustat-data-for-rare-lysosomal-storage-disorders-at-worldsymposium-2026 2026-01-22T12:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/3515fd05e02fd584/dr-reddy-s-pivots-to-biosimilars-and-glp-1-drugs-as-revlimid-revenue-cliff-approaches 2026-01-22T12:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/d7b45d153f5958a7/fda-grants-first-full-approval-for-potassium-bromide-chewable-tablets-to-treat-canine-idiopathic-epilepsy 2026-01-22T12:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/26b894f5f109815f/paltusotine-poised-for-major-market-impact-as-first-oral-acromegaly-therapy-gains-fda-approval 2026-01-22T12:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/18fb3e46958cedb2/strive-completes-225-million-follow-on-offering-rapidly-retires-92-of-semler-scientific-debt 2026-01-22T09:51:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a44958360cbc571/60-million-global-consortium-launches-to-accelerate-antibiotic-discovery-against-gram-negative-bacteria 2026-01-22T08:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/e85d8eac87df7366/biostem-technologies-acquires-biotissue-s-surgical-and-wound-care-business-for-15-million 2026-01-22T08:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/f7915f3549edebd3/sk-bioscience-partners-with-msd-and-hilleman-labs-on-30m-cepi-funded-zaire-ebola-vaccine-development 2026-01-22T08:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/fc06bf89440ef308/puma-trial-challenges-standard-heart-surgery-monitoring-with-3-7m-study-comparing-invasive-devices 2026-01-22T08:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/6b43768cfa3f845c/onward-medical-initiates-pivotal-study-for-blood-pressure-control-after-spinal-cord-injury 2026-01-22T07:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/fca81fbbfa09a4cc/pharmac-proposes-expanded-access-to-cystic-fibrosis-treatments-for-all-ages 2026-01-22T04:52:53+00:00 hourly 0.9 https://trial.medpath.com/news/46e85e9a9406c965/anteris-technologies-raises-200-million-to-advance-aortic-stenosis-treatment-with-strategic-medtronic-partnership 2026-01-22T04:52:52+00:00 hourly 0.9 https://trial.medpath.com/news/a7fb7943393a1c49/sonomotion-receives-fda-clearance-for-break-wave-non-invasive-kidney-stone-treatment-device 2026-01-22T04:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/ff0875fce460cbb2/new-dark-borosilicate-contrast-agent-shows-promise-for-enhanced-ct-imaging-of-bowel-pathologies 2026-01-22T01:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/91fd753e77957b1d/fda-grants-fast-track-designation-to-bnt113-mrna-immunotherapy-for-hpv16-positive-head-and-neck-cancer 2026-01-22T01:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/48061598d1c441cb/merck-and-cepi-launch-30-million-initiative-to-develop-more-affordable-ebola-vaccine-for-low-income-countries 2026-01-22T01:28:24+00:00 hourly 0.9 https://trial.medpath.com/news/75b0b4b4e00f822e/alterity-therapeutics-advances-ath434-toward-phase-3-trial-in-multiple-system-atrophy-with-strengthened-clinical-data 2026-01-21T20:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/bf94bb81f466b562/ocugen-closes-22-5-million-financing-to-advance-gene-therapy-pipeline-for-blindness-diseases 2026-01-21T20:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/7556fe3086c82e39/phasewell-research-partners-with-bio-behavioral-health-to-expand-neuropsychiatric-clinical-trial-access 2026-01-21T20:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/c8afdf671a5b127e/think-bioscience-raises-55m-series-a-to-develop-first-in-class-therapies-for-undruggable-targets 2026-01-21T20:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/0d74fd4c583c4c50/johnson-johnson-reports-9-1-q4-sales-growth-targets-100-5-billion-revenue-for-2026 2026-01-21T20:39:53+00:00 hourly 0.9 https://trial.medpath.com/news/2edc75d290159e01/qv-bioelectronics-secures-ps4-5m-to-advance-world-first-implantable-brain-cancer-device-into-clinical-trials 2026-01-21T20:39:52+00:00 hourly 0.9 https://trial.medpath.com/news/135d1f344882a963/infinitopes-secures-35m-to-advance-ai-powered-cancer-vaccine-for-esophageal-cancer-prevention 2026-01-21T20:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/4183ac155b0095d3/hoth-therapeutics-secures-chinese-patent-for-ht-kit-cancer-program-targeting-kit-signaling-pathways 2026-01-21T20:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/46a8f4a7d0702435/obagi-medical-launches-aloha-program-for-real-world-evaluation-of-new-hyaluronic-acid-filler 2026-01-21T20:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/6395097155774ec3/intrabio-s-levacetylleucine-achieves-primary-endpoint-in-pivotal-phase-iii-trial-for-ataxia-telangiectasia 2026-01-21T17:04:56+00:00 hourly 0.9 https://trial.medpath.com/news/951e5ec861061ed5/fda-grants-orphan-drug-designation-to-pegrizeprument-for-liver-transplant-rejection-prevention 2026-01-21T16:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/bf0a995a25768b8f/tempus-launches-ai-powered-paige-predict-for-biomarker-detection-in-digital-pathology 2026-01-21T16:14:12+00:00 hourly 0.9 https://trial.medpath.com/news/0dd22a51a4ea78f1/scynexis-receives-fda-fast-track-and-qidp-designations-for-scy-247-antifungal-therapy 2026-01-21T16:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/f4d5fbf4415521dc/revelation-biosciences-secures-fda-agreement-for-streamlined-gemini-approval-pathway-in-acute-kidney-injury 2026-01-21T16:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/e659412959cd82a6/sigachi-industries-develops-triple-drug-api-combination-for-cystic-fibrosis-treatment 2026-01-21T13:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/19f5df28c4161fcb/fluoguide-submits-ind-application-for-fg001-cancer-imaging-agent-to-begin-u-s-registration-trial 2026-01-21T13:33:58+00:00 hourly 0.9 https://trial.medpath.com/news/e48d87c24937a09a/ervimmune-raises-eur17-million-to-advance-off-the-shelf-cancer-vaccine-targeting-human-endogenous-retroviruses 2026-01-21T13:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/9da6b9bc55aad07a/io-biotech-explores-strategic-alternatives-as-cancer-vaccine-developer-faces-financial-pressures 2026-01-21T10:35:00+00:00 hourly 0.9 https://trial.medpath.com/news/db8dcacff87b5822/roche-triples-investment-to-2b-for-north-carolina-glp-1-manufacturing-plant-to-challenge-obesity-market-leaders 2026-01-21T07:14:04+00:00 hourly 0.9 https://trial.medpath.com/news/5b8c4b6729eff699/variant-bio-appoints-craig-t-basson-as-chief-medical-officer-to-accelerate-genomics-driven-drug-discovery 2026-01-21T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7db37dd4e7a57c4d/supreme-court-of-canada-to-rule-on-medical-treatment-patent-validity-in-landmark-janssen-case 2026-01-21T03:23:19+00:00 hourly 0.9 https://trial.medpath.com/news/8b46abc58053b39c/engene-secures-125-million-debt-facility-to-advance-bladder-cancer-gene-therapy-toward-fda-approval 2026-01-21T03:22:33+00:00 hourly 0.9 https://trial.medpath.com/news/50f3aa0cd061d7fe/biomodal-s-6-base-sequencing-technology-achieves-95-accuracy-in-early-stage-colorectal-cancer-detection 2026-01-21T03:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/6d0da2f79c3a417b/scribe-therapeutics-advances-crispr-cholesterol-therapy-stx-1150-to-phase-i-trials-in-mid-2026 2026-01-21T03:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/ddb5cd94d5fbd22f/isomorphic-labs-pushes-back-ai-designed-drug-clinical-trials-to-2026 2026-01-21T03:21:15+00:00 hourly 0.9 https://trial.medpath.com/news/9b971a5cc29cd8ec/genentech-expands-holly-springs-manufacturing-investment-to-2-billion-for-obesity-drug-production 2026-01-21T03:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/b6fef8aa1971e9b2/illumina-secures-medicare-reimbursement-for-comprehensive-cancer-genomic-test-at-2989-per-test 2026-01-21T03:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/5668cbe8ba6c12de/patent-disputes-highlight-innovation-challenges-in-photodynamic-therapy-and-genomic-sequencing-technologies 2026-01-21T03:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/6547d6f3c9d58fba/nccn-guidelines-now-recognize-mammaprint-testing-to-guide-anthracycline-use-in-hr-her2-breast-cancer 2026-01-21T03:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/879ef6a44b766aba/biomakers-secures-8-million-to-scale-ai-driven-precision-oncology-platform 2026-01-21T03:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/f4cc1ea088ab6233/compremium-s-non-invasive-cvp-device-receives-fda-breakthrough-designation 2026-01-21T03:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/7ca3faea0278b3a8/q1-2026-pharmaceutical-pipeline-poised-for-major-regulatory-milestones-across-multiple-therapeutic-areas 2026-01-20T16:45:11+00:00 hourly 0.9 https://trial.medpath.com/news/5e9dadacf8bc5d8f/novo-nordisk-and-aspect-biosystems-expand-partnership-to-develop-curative-cell-therapies-for-diabetes 2026-01-20T16:42:52+00:00 hourly 0.9 https://trial.medpath.com/news/34df0180349b1e2e/bristol-myers-squibb-partners-with-microsoft-to-deploy-ai-powered-lung-cancer-detection-technology 2026-01-20T16:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/5fe8fb81fee6ac2f/reunion-neuroscience-s-re104-meets-primary-endpoint-in-phase-2-postpartum-depression-trial-advances-to-phase-3 2026-01-20T16:41:44+00:00 hourly 0.9 https://trial.medpath.com/news/d066ed08f4e46c75/cipla-partners-with-immunoact-to-bring-india-s-first-indigenous-car-t-cell-therapy-to-africa 2026-01-20T16:40:46+00:00 hourly 0.9 https://trial.medpath.com/news/8b173ab4f8b1e3d1/spur-therapeutics-to-present-two-year-clinical-data-for-flt201-gene-therapy-in-gaucher-disease-at-worldsymposium 2026-01-20T16:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/39e12d63df37d467/eur60-million-ligand-ai-consortium-launches-to-accelerate-drug-discovery-through-open-ai-datasets 2026-01-20T16:39:54+00:00 hourly 0.9 https://trial.medpath.com/news/8fa7c5dd97c5efe6/polarean-expands-xenon-mri-platform-into-cardiopulmonary-drug-development-with-multi-center-ph-ild-study 2026-01-20T16:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/09dd279542941f37/bpgbio-receives-fda-orphan-drug-designation-for-bpm31510-in-primary-coq10-deficiency 2026-01-20T16:38:32+00:00 hourly 0.9 https://trial.medpath.com/news/0befcc42dcffb9e4/fda-grants-breakthrough-therapy-designation-to-lilly-s-sofetabart-mipitecan-for-platinum-resistant-ovarian-cancer 2026-01-20T16:37:36+00:00 hourly 0.9 https://trial.medpath.com/news/d4b206875fd98242/illumina-secures-cms-reimbursement-for-trusight-oncology-comprehensive-test-at-2989-55 2026-01-20T16:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/1c3eb5f9edd53254/worldwide-clinical-trials-acquires-catalyst-clinical-research-to-strengthen-oncology-capabilities 2026-01-20T16:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/55e298b3213b3ddd/cjeu-to-rule-on-critical-spc-patent-protection-case-for-veterinary-drug-development 2026-01-20T16:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/a399d69c6e0b1c5f/cytespace-africa-labs-triples-molecular-testing-capacity-to-support-clinical-trials-across-sub-saharan-africa 2026-01-20T16:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/4d68af4c47b73c85/adaptin-bio-receives-first-irb-approval-for-novel-brain-cancer-immunotherapy-aptn-101-phase-1-trial 2026-01-20T16:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/60b44c6576535a4c/shionogi-increases-viiv-healthcare-stake-to-21-7-in-2-13-billion-deal-as-pfizer-exits-hiv-joint-venture 2026-01-20T15:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/afbbafab896e60da/astrazeneca-completes-nyse-direct-listing-as-eu-recommends-imfinzi-for-gastric-cancer 2026-01-20T15:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/09977528304c8b70/moderna-merck-cancer-vaccine-maintains-49-risk-reduction-in-high-risk-melanoma-at-five-year-mark 2026-01-20T15:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/1f0e5b21215b48d9/hrv-pharma-and-haleos-labs-form-strategic-cdmo-alliance-to-accelerate-orphan-drug-api-development 2026-01-20T15:01:23+00:00 hourly 0.9 https://trial.medpath.com/news/381db026810950c7/bridge-to-life-secures-first-fda-clearance-for-hypothermic-oxygenated-perfusion-system-in-liver-transplantation 2026-01-20T15:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/aa29a7496f1e4c83/bayer-partners-with-vanderbilt-medical-center-in-five-year-drug-discovery-collaboration-for-cardiovascular-and-kidney-diseases 2026-01-20T14:56:04+00:00 hourly 0.9 https://trial.medpath.com/news/c4901ae6bcfb4750/gsk-acquires-rapt-therapeutics-for-2-2-billion-to-advance-food-allergy-treatment 2026-01-20T14:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/e024f700b912bda1/exciva-secures-eur51-million-series-b-to-advance-alzheimer-s-agitation-therapy-deraphan-into-phase-2-trials 2026-01-20T14:55:20+00:00 hourly 0.9 https://trial.medpath.com/news/812a0e3ab7a47453/exciva-secures-eur51m-series-b-to-advance-alzheimer-s-agitation-treatment-into-phase-ii 2026-01-20T14:55:17+00:00 hourly 0.9 https://trial.medpath.com/news/8ad3178b36b89800/avicanna-publishes-first-real-world-evidence-study-on-medical-cannabis-for-chronic-pain-management 2026-01-20T11:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/f66d71bf8d49322c/elekta-receives-fda-clearance-for-evo-ct-linac-system-expanding-u-s-radiation-oncology-capabilities 2026-01-20T00:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/5089892bdf1a7a01/functional-gut-clinic-launches-specialized-clinical-trials-division-to-accelerate-digestive-health-research 2026-01-20T00:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/f3c206f487a63233/nucleome-therapeutics-advances-first-in-class-inflammation-resolution-antibody-to-preclinical-development 2026-01-19T21:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/0e7a684acf309a45/florida-cancer-affiliates-launches-clinical-trials-in-bay-county-bringing-advanced-cancer-treatments-closer-to-home 2026-01-19T21:09:01+00:00 hourly 0.9 https://trial.medpath.com/news/c5c087f02f47c57f/novel-airway-scaffolds-show-promise-in-breathe-3-trial-for-severe-emphysema-treatment 2026-01-19T18:53:00+00:00 hourly 0.9 https://trial.medpath.com/news/662bcadba7bd475e/iregene-s-nouvneu001-becomes-first-ipsc-therapy-to-receive-both-fda-fast-track-and-rmat-designations-for-parkinson-s-disease 2026-01-19T16:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/a7e2272704f65c88/agomab-and-spyglass-raise-combined-350m-in-biotech-ipos-signaling-market-recovery 2026-01-19T16:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/0b399bc207d7c52c/debra-research-and-university-medical-center-groningen-launch-dedicated-clinical-trial-site-for-epidermolysis-bullosa 2026-01-19T14:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/057c443b95afe324/syngene-international-extends-strategic-bristol-myers-squibb-collaboration-through-2035 2026-01-19T08:56:39+00:00 hourly 0.9 https://trial.medpath.com/news/d25936437d9a3880/lumos-diagnostics-advances-two-key-clinical-programs-with-1-1m-in-milestone-funding 2026-01-19T08:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/01df65f19494139a/sun-pharma-pursues-10-billion-acquisition-of-women-s-health-specialist-organon 2026-01-19T08:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/ea7a9c5df35a2142/jw-pharmaceutical-secures-u-s-patent-for-novel-hair-loss-treatment-jw0061-targeting-gfra1-receptor 2026-01-19T08:55:39+00:00 hourly 0.9 https://trial.medpath.com/news/aa2be6ce4cb70dca/health-canada-proposes-streamlined-drug-approvals-through-foreign-regulatory-partnerships 2026-01-19T08:55:11+00:00 hourly 0.9 https://trial.medpath.com/news/139e04b8f90fd7ee/charles-river-laboratories-announces-strategic-acquisitions-and-leadership-changes-to-strengthen-drug-development-capabilities 2026-01-19T08:54:22+00:00 hourly 0.9 https://trial.medpath.com/news/4b7b61a544dd6593/breakthrough-in-protein-degradation-technology-reveals-molecular-mechanisms-for-targeting-undruggable-diseases 2026-01-19T06:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/64f4150f0eedbb31/korean-anti-cancer-resistance-drug-oct-598-begins-phase-1-clinical-trials-through-public-private-partnership 2026-01-18T16:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/8c8f61be8150c853/pembrolizumab-lenvatinib-combination-shows-40-response-rate-in-recurrent-gynecologic-clear-cell-carcinoma 2026-01-17T20:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/236610f7a4172811/alto-neuroscience-secures-key-patent-for-alto-207-depression-treatment-extending-ip-protection-to-mid-2040s 2026-01-17T18:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/75671ea4edc2d957/comprehensive-lancet-review-finds-no-link-between-paracetamol-use-during-pregnancy-and-autism-or-adhd-in-children 2026-01-17T18:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/86f7ac736f7a07b5/agomab-therapeutics-raises-200-million-in-ipo-to-advance-fibrotic-disease-therapies 2026-01-17T15:49:48+00:00 hourly 0.9 https://trial.medpath.com/news/c2906d38f5961e25/fda-approves-extended-five-year-use-of-nexplanon-contraceptive-implant 2026-01-17T07:52:01+00:00 hourly 0.9 https://trial.medpath.com/news/93a1089a822e920c/moderna-advances-cancer-pipeline-with-mrna-4106-immunotherapy-trial-in-solid-tumors 2026-01-17T03:52:48+00:00 hourly 0.9 https://trial.medpath.com/news/08d3e46b25c4a184/purdue-researchers-develop-freeze-dried-mrna-delivery-system-for-cancer-therapy 2026-01-17T03:52:41+00:00 hourly 0.9 https://trial.medpath.com/news/1b88128a130f3f09/novartis-ianalumab-receives-fda-breakthrough-therapy-designation-for-sjogren-s-disease 2026-01-16T20:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/362787e78e918400/fda-grants-full-approval-to-laverdia-first-oral-treatment-for-canine-lymphoma 2026-01-16T20:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/ca58a2101a18189d/profusa-expands-lumee-oxygen-monitoring-platform-through-strategic-partnerships-and-commercial-launch 2026-01-16T17:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/3adf1b5a6eb2f664/varenicline-shows-gender-specific-efficacy-for-cannabis-use-disorder-in-phase-2-trial 2026-01-16T17:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/3953b0b09b451433/tirzepatide-shows-superior-glaucoma-protection-compared-to-glp-1-receptor-agonists-in-type-2-diabetes-patients 2026-01-16T16:08:29+00:00 hourly 0.9 https://trial.medpath.com/news/be4bb7032acc6cb1/federal-judge-rejects-moderna-s-bid-to-shift-covid-19-vaccine-patent-liability-to-us-government 2026-01-16T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/42364a4ef010c466/immunitybio-s-cd19-car-nk-therapy-achieves-15-month-complete-response-in-waldenstrom-lymphoma 2026-01-16T16:08:21+00:00 hourly 0.9 https://trial.medpath.com/news/9a71dafe77dc39e8/hemogenyx-raises-ps2-5m-to-advance-car-t-therapy-for-acute-myeloid-leukemia 2026-01-16T16:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/a8daa03e8b3feeb2/penpulimab-plus-anlotinib-shows-promise-in-resectable-nsclc-phase-ii-trial 2026-01-16T16:07:13+00:00 hourly 0.9 https://trial.medpath.com/news/7ddb82e8c422497b/abemaciclib-shows-promise-in-aggressive-meningiomas-with-specific-genetic-mutations 2026-01-16T16:04:30+00:00 hourly 0.9 https://trial.medpath.com/news/cb01def141f1dfc1/global-clinical-trials-landscape-shows-strong-activity-in-gout-and-bronchiectasis-research 2026-01-16T16:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/abd949afa07b5be5/autobahn-therapeutics-presents-preclinical-data-supporting-elunetirom-s-novel-neuroplasticity-mechanism-for-depression-treatment 2026-01-16T15:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/e6b2215150f8d679/onemednet-s-real-world-data-powers-fda-clearance-of-ai-powered-brain-hemorrhage-detection-software 2026-01-16T14:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/b3c29358418be059/qps-holdings-implements-oracle-argus-platform-to-enhance-clinical-trial-safety-management 2026-01-16T13:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/166176869d2769c9/novel-oral-drug-tlc-2716-reduces-triglycerides-by-38-and-remnant-cholesterol-by-61-in-phase-1-trial 2026-01-16T13:00:15+00:00 hourly 0.9 https://trial.medpath.com/news/10847e61ff16da7a/large-uk-trial-finds-fda-cleared-adhd-device-ineffective-despite-safety-profile 2026-01-16T12:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/6acb97c511c04195/nous-209-neoantigen-vaccine-shows-promise-for-cancer-prevention-in-lynch-syndrome-carriers 2026-01-16T12:59:47+00:00 hourly 0.9 https://trial.medpath.com/news/a644a9a47d084962/interim-analysis-shows-no-safety-concerns-for-rsv-vaccine-during-pregnancy 2026-01-16T12:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/b770844baab555df/alteogen-nears-major-licensing-deal-for-subcutaneous-drug-delivery-platform-alt-b4 2026-01-16T12:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/d4dca596b2ed2c45/brenig-therapeutics-initiates-first-in-human-trial-of-brain-selective-nlrp3-inhibitor-bt-409-for-neurodegenerative-diseases 2026-01-16T12:58:23+00:00 hourly 0.9 https://trial.medpath.com/news/6ae7b44c2a564ecb/ingrezza-demonstrates-nearly-two-fold-higher-vmat2-target-occupancy-than-austedo-xr-in-head-to-head-study 2026-01-16T12:57:43+00:00 hourly 0.9 https://trial.medpath.com/news/6beeb918c856a4c0/biomarin-prices-850-million-senior-notes-to-fund-amicus-therapeutics-acquisition 2026-01-16T06:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/9cf95db8c07a4bc3/leads-biolabs-pd-l1-4-1bb-bispecific-antibody-receives-fda-fast-track-designation-for-rare-neuroendocrine-cancer 2026-01-16T04:27:58+00:00 hourly 0.9 https://trial.medpath.com/news/3ee63838a9eef235/fda-approves-expanded-indications-for-cerapedics-pearlmatrix-bone-graft-across-all-major-lumbar-fusion-procedures 2026-01-16T04:27:56+00:00 hourly 0.9 https://trial.medpath.com/news/d88cd51737a1c5e2/frontage-cdmo-completes-gmp-validation-for-new-manufacturing-facility-supporting-clinical-and-commercial-production 2026-01-16T04:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/edd82af5f9f4b242/network-meta-analysis-reveals-pegozafermin-leads-mash-treatment-rankings-for-fibrosis-regression-and-disease-resolution 2026-01-16T04:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/8385275c2e497a59/injectable-hiv-treatment-shows-high-acceptance-among-adolescents-in-global-clinical-trial 2026-01-16T04:26:09+00:00 hourly 0.9 https://trial.medpath.com/news/06b36519a0c14cea/orion-projects-nubeqa-sales-could-exceed-eur1-billion-annually-as-prostate-cancer-drug-drives-2026-growth 2026-01-15T22:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/1c534c64f14a9c17/sanofi-prepares-enhanced-takeover-bid-for-ocular-therapeutix-following-rejected-16-per-share-offer 2026-01-15T22:04:12+00:00 hourly 0.9 https://trial.medpath.com/news/03e38ba74d02ab32/fda-requests-febrile-seizure-warning-for-six-major-flu-vaccines-following-post-marketing-safety-analysis 2026-01-15T22:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/92944b4455ade1af/regeneron-advances-regn9533-blood-clot-treatment-through-phase-1-while-terminating-heart-failure-program 2026-01-15T22:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/b5bc55f394b38ffe/qli5-therapeutics-secures-eur6-2m-to-advance-novel-proteasome-inhibitor-adc-platform 2026-01-15T22:02:23+00:00 hourly 0.9 https://trial.medpath.com/news/071f6d45fd54a725/remsleep-secures-expanded-fda-clearance-and-medicare-coding-for-deltawave-sleep-therapy-system 2026-01-15T22:02:22+00:00 hourly 0.9 https://trial.medpath.com/news/fb008a14fed71dd6/fda-approves-generic-mifepristone-as-senate-committee-debates-drug-safety-protocols 2026-01-15T22:01:12+00:00 hourly 0.9 https://trial.medpath.com/news/2000100d179545c9/phase-3-endure-trial-shows-no-benefit-of-ropeginterferon-alfa-2b-maintenance-after-tki-cessation-in-cml 2026-01-15T18:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/313efa282db7eb1a/hanchorbio-partners-with-wuxi-biologics-to-accelerate-next-generation-fusion-protein-development 2026-01-15T16:41:51+00:00 hourly 0.9 https://trial.medpath.com/news/efc9dbd1a090b979/cardiac-biotech-solutions-advances-mycardia-at-cardiac-monitor-toward-china-market-entry-with-nmpa-submission 2026-01-15T16:41:21+00:00 hourly 0.9 https://trial.medpath.com/news/02773e653bf1e66c/lmu-researchers-develop-hybrid-nanocarrier-system-for-inhalable-mrna-vaccines 2026-01-15T16:41:14+00:00 hourly 0.9 https://trial.medpath.com/news/fe85f02847734a4c/galderma-presents-phase-3-data-on-relfydess-neuromodulator-at-toxins-2026-demonstrating-superior-efficacy-and-duration 2026-01-15T16:40:50+00:00 hourly 0.9 https://trial.medpath.com/news/af6cc6948fd8b56a/boston-scientific-acquires-penumbra-for-14-5-billion-to-expand-vascular-pipeline 2026-01-15T16:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/2de5abe94ca2d0dd/ritlecitinib-shows-consistent-vitiligo-repigmentation-across-diverse-patient-subgroups-in-phase-2b-analysis 2026-01-15T16:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/dce892850666480b/propanc-biopharma-publishes-peer-reviewed-research-on-prp-s-impact-on-pancreatic-cancer-tumor-microenvironment 2026-01-15T16:40:27+00:00 hourly 0.9 https://trial.medpath.com/news/8799d394657adb45/clarity-pharmaceuticals-secure-trial-shows-promising-results-for-advanced-prostate-cancer-treatment 2026-01-15T16:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/5df537a5c8556b36/bd-receives-fda-clearance-for-multi-modality-breast-biopsy-system-market-launch-planned-for-early-2026 2026-01-15T16:39:25+00:00 hourly 0.9 https://trial.medpath.com/news/0825d46127921b8c/bristol-myers-squibb-partners-with-immunai-to-deploy-ai-for-immune-response-analysis-in-clinical-trials 2026-01-15T16:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/27757d2fffc1ec2a/first-u-s-patient-receives-alveltamig-novel-trispecific-t-cell-engager-for-small-cell-lung-cancer 2026-01-15T16:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/7a5fa7bed4deefa2/korea-university-researchers-revive-nk1-receptor-as-depression-target-through-novel-molecular-design 2026-01-15T16:36:14+00:00 hourly 0.9 https://trial.medpath.com/news/1e5d1e7b2662a227/australian-researchers-report-positive-phase-ii-results-for-novel-sepsis-drug-stc3141 2026-01-15T16:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/da1db9eaf670b9db/sanofi-secures-chinese-approval-for-two-breakthrough-therapies-targeting-rare-cardiovascular-and-metabolic-disorders 2026-01-15T16:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/6463c85a8ab37060/fda-fast-tracks-leucovorin-for-autism-treatment-despite-limited-evidence 2026-01-15T16:35:28+00:00 hourly 0.9 https://trial.medpath.com/news/bcaad039fc40c3b4/arizona-pharmacy-sues-eli-lilly-and-novo-nordisk-over-alleged-glp-1-market-suppression 2026-01-15T14:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/880b10f86fb3dda7/saudi-arabia-becomes-first-country-to-approve-anktiva-for-lung-cancer-treatment 2026-01-15T09:01:49+00:00 hourly 0.9 https://trial.medpath.com/news/a8e0a0db0e5f51d4/delhi-high-court-upholds-ban-on-triple-drug-diabetes-combinations-supreme-court-to-review 2026-01-15T09:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/483a5e6dda781524/dr-reddy-s-launches-first-to-market-generic-olopatadine-0-7-eye-drops-in-us 2026-01-15T05:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/db003ad9beceaf84/experimental-herpes-virus-based-therapy-shows-promise-in-glioblastoma-clinical-trial 2026-01-15T05:02:45+00:00 hourly 0.9 https://trial.medpath.com/news/1718ed51f08eef6b/aim-vaccine-completes-phase-iii-trials-for-high-efficiency-diploid-rabies-vaccine-with-superior-efficacy 2026-01-15T05:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/21620f51fc317f02/samsung-bioepis-advances-first-novel-adc-targeting-nectin-4-into-phase-1-trials-following-fda-clearance 2026-01-15T05:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/0ff90e6f4968af0a/amphastar-pharmaceuticals-advances-proprietary-pipeline-with-novel-eye-drop-and-cancer-therapies 2026-01-15T05:01:11+00:00 hourly 0.9 https://trial.medpath.com/news/48e78d56b476f16e/gradalis-vigil-immunotherapy-shows-nearly-six-year-survival-benefit-in-ovarian-cancer-subset 2026-01-15T00:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/6f1c07b40c31cb38/high-dose-flu-vaccine-reduces-hospitalizations-in-older-adults-with-diabetes-danish-trial-shows 2026-01-15T00:31:49+00:00 hourly 0.9 https://trial.medpath.com/news/ebceb39d151177d8/rina-s-shows-50-response-rate-in-heavily-pretreated-endometrial-cancer-regardless-of-target-expression 2026-01-15T00:31:43+00:00 hourly 0.9 https://trial.medpath.com/news/a168d0ff2e5a5118/adolore-biotherapeutics-receives-fda-orphan-drug-designation-for-gene-therapy-targeting-erythromelalgia 2026-01-15T00:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/3c42b00787b0af0c/alfasigma-acquires-exclusive-rights-to-adibelivir-for-hsv-encephalitis-in-eur125-million-deal 2026-01-15T00:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/7aeaf9684fdebcb8/iotamotion-receives-fda-clearance-for-pediatric-cochlear-implant-robot-expanding-access-for-children 2026-01-15T00:30:15+00:00 hourly 0.9 https://trial.medpath.com/news/4aec4fbbacbb1cab/vagus-nerve-stimulation-shows-lasting-benefits-for-severe-treatment-resistant-depression-in-two-year-study 2026-01-15T00:23:30+00:00 hourly 0.9 https://trial.medpath.com/news/e9969a2955a6a30e/adial-pharmaceuticals-secures-patent-protection-for-ad04-alcohol-use-disorder-therapy-through-2045 2026-01-15T00:22:24+00:00 hourly 0.9 https://trial.medpath.com/news/5144eae3cb4478be/ultrahuman-and-click-therapeutics-launch-world-s-first-biomarker-driven-migraine-management-tool 2026-01-15T00:22:23+00:00 hourly 0.9 https://trial.medpath.com/news/1defd2997c8d0e6f/fda-clears-rayner-s-sophi-wireless-phacoemulsification-system-for-u-s-cataract-surgery-market 2026-01-15T00:20:02+00:00 hourly 0.9 https://trial.medpath.com/news/e96f60cc7d0530ca/caldera-therapeutics-launches-with-112-5m-to-advance-first-in-class-bispecific-ibd-therapy 2026-01-15T00:19:59+00:00 hourly 0.9 https://trial.medpath.com/news/134c571e5bd81a7f/aragen-life-sciences-shifts-biologics-operations-to-india-as-global-pharma-rebalances-supply-chains 2026-01-14T20:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/b989f2592b7e9e0a/blood-test-identifies-small-cell-lung-cancer-patients-who-will-respond-to-tarlatamab-immunotherapy 2026-01-14T17:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/0a1794cfd2b9c7f5/novartis-secures-long-term-actinium-225-supply-deal-to-support-radioligand-therapy-expansion 2026-01-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/3027b17febf5971c/fresenius-kabi-partners-with-tq-therapeutics-to-develop-point-of-care-cell-therapy-manufacturing-system 2026-01-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/1c1ea36068fbfc70/astrazeneca-advances-weight-loss-drug-elecoglipron-to-phase-iii-as-company-targets-80b-revenue-by-2030 2026-01-14T17:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/fbd4e6afaaa90703/nuclera-secures-87-million-series-c-extension-to-advance-ai-enabled-antibody-engineering-platform 2026-01-14T17:03:29+00:00 hourly 0.9 https://trial.medpath.com/news/5c4b5a200558d004/sandoz-secures-european-approval-for-ondibta-insulin-glargine-biosimilar-targeting-66-million-european-diabetes-patients 2026-01-14T17:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/1ef24e0a5b73d42c/european-regulators-recommend-olumiant-for-adolescent-alopecia-areata-treatment 2026-01-14T13:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/1cedc55d42f55abd/c4-therapeutics-advances-cemsidomide-through-phase-2-development-as-potential-best-in-class-multiple-myeloma-treatment 2026-01-14T13:03:42+00:00 hourly 0.9 https://trial.medpath.com/news/d296d68ba1dfc371/jazz-pharmaceuticals-reports-record-4-3-billion-revenue-in-2025-prepares-zanidatamab-launch-for-gastroesophageal-cancer 2026-01-14T13:02:39+00:00 hourly 0.9 https://trial.medpath.com/news/e087a4689df63d15/tbd09-tuberculosis-drug-candidate-completes-phase-i-trial-shows-promise-as-linezolid-alternative 2026-01-14T13:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/507ef088adb623ca/fda-breakthrough-device-program-maintains-steady-pace-as-medicare-coverage-debate-intensifies 2026-01-14T13:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/c6a575f5c767eb7f/first-uk-patient-receives-nhs-funded-car-t-therapy-for-aggressive-leukemia-at-manchester-royal-infirmary 2026-01-14T13:01:33+00:00 hourly 0.9 https://trial.medpath.com/news/6043d03965b3f267/amplifi-vascular-receives-fda-breakthrough-device-designation-for-dialysis-access-innovation 2026-01-14T05:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/57e6739545fa7f2c/rituximab-shows-long-term-effectiveness-with-extended-dosing-intervals-in-relapsing-multiple-sclerosis 2026-01-14T05:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/0136fb40cbea39ee/roche-outlines-ambitious-pipeline-strategy-with-blockbuster-potential-assets-through-2031 2026-01-14T05:01:48+00:00 hourly 0.9 https://trial.medpath.com/news/c80e96843e9de684/gsk-accelerates-ai-driven-drug-discovery-strategy-with-950m-35pharma-acquisition-and-noetik-partnership 2026-01-14T03:03:37+00:00 hourly 0.9 https://trial.medpath.com/news/b42c4706aa2c4486/gilead-s-diverse-hiv-pipeline-offers-competitive-advantage-with-seven-candidates-in-development 2026-01-14T03:03:02+00:00 hourly 0.9 https://trial.medpath.com/news/4c6f48242b3021be/allele-biotechnology-partners-with-uc-san-diego-on-25-8m-arpa-h-project-to-develop-3d-bioprinted-livers-for-transplantation 2026-01-14T01:02:30+00:00 hourly 0.9 https://trial.medpath.com/news/d516b75075311095/small-intracellular-vesicles-outperform-extracellular-vesicles-in-drug-delivery-and-retinal-protection 2026-01-14T00:04:19+00:00 hourly 0.9 https://trial.medpath.com/news/26e7564507803238/acadia-pharmaceuticals-projects-1-7-billion-revenue-by-2028-advances-alzheimer-s-psychosis-pipeline 2026-01-14T00:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/a2993c0715814e6a/adimab-reports-11-new-clinical-programs-in-2025-reaching-89-total-programs-with-six-approved-therapies 2026-01-14T00:04:13+00:00 hourly 0.9 https://trial.medpath.com/news/0262b7699e39f12e/aptar-s-nasal-delivery-technology-advances-castlevax-phase-ii-covid-19-vaccine-trial 2026-01-14T00:03:26+00:00 hourly 0.9 https://trial.medpath.com/news/b8627ca3a1f1f092/axol-bioscience-secures-2-8m-to-expand-ipsc-disease-model-platform-and-us-operations 2026-01-13T21:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/117d05819dbaabd7/oramed-and-lifeward-announce-strategic-merger-creating-diversified-biomedical-platform 2026-01-13T21:39:39+00:00 hourly 0.9 https://trial.medpath.com/news/5bdd3be4aac17efc/soley-therapeutics-raises-200m-series-c-to-advance-cell-stress-sensing-platform-and-aml-drug-candidate 2026-01-13T20:09:50+00:00 hourly 0.9 https://trial.medpath.com/news/10c668ada9bc2732/bd-invests-110-million-in-nebraska-manufacturing-to-support-biologic-drug-supply-chain 2026-01-13T20:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/98b8335249ea8feb/astrazeneca-acquires-modella-ai-in-first-major-pharma-ai-deal-to-accelerate-oncology-drug-development 2026-01-13T20:09:12+00:00 hourly 0.9 https://trial.medpath.com/news/54e37e46b4d09098/cepi-oxford-and-serum-institute-create-world-s-largest-rift-valley-fever-vaccine-reserve-amid-west-africa-outbreak 2026-01-13T20:09:06+00:00 hourly 0.9 https://trial.medpath.com/news/272bf334322c8cc2/bayer-reports-landmark-year-with-five-pivotal-drug-approvals-accelerates-growth-strategy-across-oncology-and-cardiovascular-medicine 2026-01-13T20:08:47+00:00 hourly 0.9 https://trial.medpath.com/news/0ea84f27af3704ef/fda-s-mifepristone-oversight-found-to-be-science-based-in-comprehensive-document-review 2026-01-13T20:08:02+00:00 hourly 0.9 https://trial.medpath.com/news/1b34366b8b93d750/fda-grants-breakthrough-therapy-designation-to-ipsen-s-ipn60340-for-first-line-acute-myeloid-leukemia 2026-01-13T20:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/b495e66c98531f9f/cedars-sinai-develops-ai-powered-platform-to-predict-drug-toxicity-using-human-organoids 2026-01-13T20:08:00+00:00 hourly 0.9 https://trial.medpath.com/news/fabf0e16d8843de2/fda-requests-removal-of-suicide-risk-warnings-from-glp-1-weight-loss-medications-following-comprehensive-safety-review 2026-01-13T20:03:06+00:00 hourly 0.9 https://trial.medpath.com/news/556fd9399e2c5bc6/gardp-and-debiopharm-partner-to-develop-novel-first-in-class-antibiotic-for-multidrug-resistant-gonorrhea 2026-01-13T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/336c80368dd09441/novel-drug-candidate-evt0185-shows-promise-for-reversing-liver-fibrosis-in-preclinical-studies 2026-01-13T17:08:01+00:00 hourly 0.9 https://trial.medpath.com/news/5e4604dc22027351/marea-therapeutics-reports-positive-phase-1-results-for-mar002-acromegaly-treatment 2026-01-13T16:11:21+00:00 hourly 0.9 https://trial.medpath.com/news/43104bf1eeb023b2/european-patent-office-approves-iconovo-s-icopre-r-inhaler-patent-application-for-generic-ellipta-alternative 2026-01-13T16:11:12+00:00 hourly 0.9 https://trial.medpath.com/news/f16aa2a71bfde26e/applied-cells-and-immuneel-therapeutics-partner-to-develop-affordable-car-t-therapies-for-india-and-global-markets 2026-01-13T16:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/ae8c5b65a506dd14/novel-tgf-b1-inhibitor-linavonkibart-shows-promise-in-overcoming-immune-checkpoint-resistance 2026-01-13T16:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/0bb4c43a37c74f58/experimental-compound-shows-promise-for-myotonic-dystrophy-type-1-treatment-advances-to-clinical-trial 2026-01-13T16:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/51f239a644b6a3b8/henlius-submits-fifth-us-product-for-fda-review-as-bevacizumab-biosimilar-hlx04-receives-bla-acceptance 2026-01-13T16:09:56+00:00 hourly 0.9 https://trial.medpath.com/news/9aae61e1cc4eff7a/xtl-biopharmaceuticals-acquires-85-of-neuronos-in-32-5m-deal-to-target-autism-therapeutics-market 2026-01-13T16:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/e941fe50b8499923/converge-bio-secures-25m-series-a-to-accelerate-ai-driven-drug-discovery-platform 2026-01-13T16:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/4aaf7f72b282b408/boehringer-ingelheim-advances-first-in-class-il-11-inhibitor-bi-765423-to-phase-ii-trial-for-idiopathic-pulmonary-fibrosis 2026-01-13T16:08:14+00:00 hourly 0.9 https://trial.medpath.com/news/c9504bb3eb571471/illumina-launches-billion-cell-atlas-to-accelerate-ai-driven-drug-discovery 2026-01-13T16:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/f52b7fbdd0da264d/johnson-johnson-presents-new-depression-treatment-data-at-acnp-2026-meeting 2026-01-13T16:08:06+00:00 hourly 0.9 https://trial.medpath.com/news/e648864355913648/fda-approves-rha-dynamic-volume-for-midface-contour-enhancement-in-adults 2026-01-13T16:08:05+00:00 hourly 0.9 https://trial.medpath.com/news/fcc19148e130d4be/cardiol-therapeutics-reaches-50-enrollment-in-phase-iii-maveric-trial-for-recurrent-pericarditis 2026-01-13T16:04:33+00:00 hourly 0.9 https://trial.medpath.com/news/a197e884329d611b/cassava-sciences-publishes-phase-3-simufilam-results-in-alzheimer-s-disease-reveals-biomarker-screening-challenges 2026-01-13T16:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/73c3a234de0cfda7/radiotherapeutics-poised-for-major-market-expansion-as-industry-addresses-infrastructure-challenges 2026-01-13T12:37:58+00:00 hourly 0.9 https://trial.medpath.com/news/fe17b7fc9d1edc11/gates-foundation-awards-grant-to-hongene-biotech-for-patent-free-mrna-vaccine-components 2026-01-13T12:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/592970d0b81c8130/fda-clears-heartlung-s-ai-cvd-platform-for-comprehensive-opportunistic-screening-across-multiple-disease-domains 2026-01-13T08:05:26+00:00 hourly 0.9 https://trial.medpath.com/news/ebaf6dd1aaf9e109/lyfesci-acquires-clinically-media-to-integrate-patient-recruitment-into-end-to-end-clinical-trial-services 2026-01-13T08:05:20+00:00 hourly 0.9 https://trial.medpath.com/news/7c5a22dda8cbc3ac/travere-therapeutics-reports-record-filspari-sales-and-prepares-for-fsgs-approval-decision 2026-01-13T05:07:46+00:00 hourly 0.9 https://trial.medpath.com/news/d4b12deeeefc5782/mediwound-advances-escharex-phase-iii-trial-and-expands-manufacturing-capacity-ahead-of-key-2026-milestones 2026-01-13T05:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/e32eccd0f16abb84/medicus-pharma-secures-improved-teverelix-license-terms-and-reports-promising-phase-1-data-in-women 2026-01-13T01:07:19+00:00 hourly 0.9 https://trial.medpath.com/news/890d3e05c242e583/hippocratic-ai-expands-life-sciences-operations-with-grove-ai-acquisition-and-strategic-leadership-appointments 2026-01-13T00:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/d594b05b5b619aa1/revolution-medicines-reportedly-in-32-billion-acquisition-talks-with-merck-as-big-pharma-m-a-activity-surges 2026-01-13T00:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/d851016df53bbba7/yoga-accelerates-opioid-withdrawal-recovery-by-4-4-times-in-clinical-trial 2026-01-12T21:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/f3c87ac4f99b9064/avenue-biosciences-raises-5-7m-to-scale-high-throughput-protein-engineering-platform 2026-01-12T21:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/782cc1529427e74c/uae-becomes-second-country-globally-to-approve-dual-action-heart-failure-drug-inpefa 2026-01-12T21:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/97a31f0c79c60ee1/skye-bioscience-outlines-2026-clinical-roadmap-for-obesity-drug-nimacimab-following-positive-phase-2a-results 2026-01-12T21:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/b6a8cc622efcc192/neurelis-reports-transformational-growth-with-valtoco-expansion-and-patent-extensions-through-2032 2026-01-12T21:12:31+00:00 hourly 0.9 https://trial.medpath.com/news/67ce8ff47d484420/turn-therapeutics-advances-phase-2-atopic-dermatitis-trial-with-first-in-class-il-36-il-31-inhibitor-gx-03 2026-01-12T21:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/628be9590040cb84/bayer-acquires-pan-amyloid-imaging-agents-from-attralus-to-advance-cardiac-amyloidosis-diagnosis 2026-01-12T21:12:08+00:00 hourly 0.9 https://trial.medpath.com/news/d095bdb7413fbb6c/humana-s-centerwell-pharmacy-partners-with-eli-lilly-to-expand-employer-based-access-to-obesity-medications 2026-01-12T21:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/75382c5319237f70/spyre-therapeutics-accelerates-ibd-pipeline-with-six-proof-of-concept-readouts-expected-in-2026 2026-01-12T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/2721b4aab7cf3af2/whole-genome-sequencing-algorithm-outperforms-standard-tests-for-predicting-parp-inhibitor-response 2026-01-12T17:10:25+00:00 hourly 0.9 https://trial.medpath.com/news/293f7d1a8869b82b/mindmed-rebrands-as-definium-therapeutics-prepares-for-three-phase-3-psychedelic-therapy-readouts-in-2026 2026-01-12T17:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/0e7606e56c97b9bb/nuvation-bio-s-ibtrozi-demonstrates-strong-commercial-performance-with-432-new-patients-in-first-six-months 2026-01-12T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/8b41c7cae6c0afcb/radiopharm-theranostics-increases-stake-in-joint-venture-as-b7h3-targeting-radiopharmaceutical-betabart-advances-to-phase-i-trial 2026-01-12T17:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/c0d8f1ee941775a5/nuvation-bio-partners-with-eisai-in-eur195-million-deal-to-expand-taletrectinib-global-reach-for-ros1-nsclc 2026-01-12T17:10:10+00:00 hourly 0.9 https://trial.medpath.com/news/98be2211c3c53955/obi-pharma-and-tegmine-therapeutics-form-global-license-partnership-for-novel-glycan-targeting-adc 2026-01-12T17:09:18+00:00 hourly 0.9 https://trial.medpath.com/news/a0539f78a07cea7f/precede-biosciences-raises-83-5m-to-scale-blood-based-precision-diagnostics-platform-for-next-generation-cancer-therapies 2026-01-12T16:11:16+00:00 hourly 0.9 https://trial.medpath.com/news/713a8f8b06978d36/vidac-pharma-secures-uspto-patent-for-novel-hexokinase-2-mitochondrial-interaction-modulators 2026-01-12T16:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/eb3e93e629c37133/fda-rejects-atara-biotherapeutics-rare-blood-cancer-therapy-despite-prior-internal-support 2026-01-12T16:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/054a995ae462d942/france-expands-national-compassionate-access-for-agenus-botensilimab-balstilimab-combination-to-include-ovarian-cancer-and-soft-tissue-sarcomas 2026-01-12T16:09:44+00:00 hourly 0.9 https://trial.medpath.com/news/c8a10149770d524b/abcellera-advances-abcl635-to-phase-2-trial-for-non-hormonal-menopause-treatment 2026-01-12T16:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/c56bce302afb6d54/b-flexion-life-sciences-acquires-majority-stake-in-radius-health-consolidating-ownership-of-tymlos-osteoporosis-treatment 2026-01-12T16:09:29+00:00 hourly 0.9 https://trial.medpath.com/news/520ea9b8d18e1e89/pacbio-partners-with-n-lorem-foundation-and-esperare-to-advance-personalized-aso-therapies-for-ultra-rare-genetic-diseases 2026-01-12T16:09:28+00:00 hourly 0.9 https://trial.medpath.com/news/2d5f12a08f799930/scineuro-and-novartis-strike-1-65-billion-alzheimer-s-partnership-for-blood-brain-barrier-technology 2026-01-12T16:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/12b46071a14c9a90/novartis-acquires-chinese-biotech-s-radioligand-therapy-asset-in-50-million-deal 2026-01-12T16:09:20+00:00 hourly 0.9 https://trial.medpath.com/news/e1358dc219100af2/abbvie-commits-555-million-to-expand-u-s-manufacturing-capabilities-with-arizona-acquisition-and-illinois-facility-expansion 2026-01-12T16:09:17+00:00 hourly 0.9 https://trial.medpath.com/news/8d3c34da9f3f9065/outsee-secures-ps2-5m-seed-funding-and-partners-with-o2h-discovery-to-advance-ai-driven-drug-target-discovery 2026-01-12T16:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/e1b96dc14308abaf/lexeo-therapeutics-reports-promising-phase-i-ii-data-for-gene-therapy-lx2020-in-rare-heart-disease 2026-01-12T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/da9a7751de1a4649/kailera-therapeutics-initiates-global-phase-3-trials-for-dual-glp-1-gip-obesity-drug-following-strong-chinese-study-results 2026-01-12T16:08:50+00:00 hourly 0.9 https://trial.medpath.com/news/d16b3b1d8e333dd4/abbvie-secures-5-6-billion-licensing-deal-for-novel-pd-1-vegf-bispecific-antibody-rc148 2026-01-12T16:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/a0d8b28de73e7166/tempus-expands-precision-oncology-partnerships-with-northwestern-medicine-and-nyu-langone-health 2026-01-12T16:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/d88c8f6a506a1ec6/ionis-pharmaceuticals-reports-strong-2025-performance-and-outlines-ambitious-2026-pipeline-milestones 2026-01-12T16:08:16+00:00 hourly 0.9 https://trial.medpath.com/news/1eb090949b3a3fb7/fda-grants-orphan-drug-designation-to-novel-fascin-inhibitor-np-g2-044-for-pancreatic-cancer-treatment 2026-01-12T16:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/ea82d7d13d23ca4b/medtronic-receives-fda-clearance-for-minimed-go-smart-mdi-system-with-abbott-s-instinct-sensor 2026-01-12T16:08:08+00:00 hourly 0.9 https://trial.medpath.com/news/a0429bf3d1c54ea1/sebela-pharmaceuticals-submits-nda-for-tegoprazan-novel-p-cab-showing-superior-gerd-treatment-efficacy 2026-01-12T16:08:03+00:00 hourly 0.9 https://trial.medpath.com/news/543393886555aadf/an2-therapeutics-receives-fda-clearance-for-epetraborole-trial-in-mycobacterium-abscessus-lung-disease 2026-01-12T16:07:44+00:00 hourly 0.9 https://trial.medpath.com/news/a238e29c7523a751/suvoda-advances-clinical-trial-technology-with-ai-integration-and-patient-centric-platform-following-greenphire-merger 2026-01-12T16:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/6f4897e5b79b41a9/amphastar-secures-exclusive-rights-to-synthetic-acth-analog-amp-110-in-158-million-deal 2026-01-12T12:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/a4850c24ee5ab2ed/tucatinib-trastuzumab-combination-shows-promise-in-her2-positive-ras-wild-type-colorectal-cancer 2026-01-12T12:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/613efbbea0535496/alembic-pharmaceuticals-receives-fda-tentative-approval-for-400mg-bosutinib-cancer-treatment 2026-01-12T12:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/edc9da5571457ea6/fabentech-receives-first-ever-marketing-authorization-for-ricimed-revolutionary-ricin-poisoning-antidote 2026-01-12T12:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/fba12d3897887a8b/apnimed-prepares-fda-filing-for-first-ever-sleep-apnea-pill-following-successful-phase-3-trials 2026-01-12T10:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/c0d196777ea6cbaf/oricell-therapeutics-raises-70m-series-c1-to-advance-gpc3-targeted-car-t-therapy-for-hepatocellular-carcinoma 2026-01-12T09:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/370eebc480f9cf53/enginzyme-and-agc-develop-scalable-manufacturing-process-for-critical-mrna-vaccine-component 2026-01-12T09:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/9fead0966cd349f0/australian-researchers-develop-precision-immunotherapy-for-myelofibrosis-blood-cancer 2026-01-12T09:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/7e18ad3dd9bd83f1/advicenne-secures-five-year-marketing-authorization-renewal-for-sibnayal-in-european-union 2026-01-12T09:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/18358a96d78bae7b/biocon-receives-fda-approval-for-generic-everolimus-tablets-for-rare-neurological-disorder 2026-01-12T09:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/acadbfd52028434e/fda-announces-flexible-manufacturing-requirements-for-cell-and-gene-therapies-to-accelerate-innovation 2026-01-12T04:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/f283c3ffd2f318b0/ubc-acquires-evidinno-outcomes-research-to-strengthen-real-world-evidence-and-health-economics-capabilities 2026-01-12T04:19:13+00:00 hourly 0.9 https://trial.medpath.com/news/6b0e88546825b57a/lynk-pharmaceuticals-reports-positive-phase-iii-results-for-zemprocitinib-in-rheumatoid-arthritis 2026-01-12T04:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/6c810fcaae1bc18a/day-one-biopharmaceuticals-reports-strong-ojemda-revenue-growth-and-expands-pipeline-through-mersana-acquisition 2026-01-12T01:14:57+00:00 hourly 0.9 https://trial.medpath.com/news/1e63a5a0ae792457/anthropic-launches-claude-for-healthcare-with-medical-record-integration-challenging-openai-in-healthcare-ai-market 2026-01-12T00:15:24+00:00 hourly 0.9 https://trial.medpath.com/news/50f678ca3d6527b6/mbx-biosciences-advances-multi-program-pipeline-with-phase-3-hypoparathyroidism-trial-and-novel-obesity-therapies 2026-01-12T00:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/2bae51d40152b076/alamar-biosciences-secures-50m-financing-to-advance-precision-proteomics-platform-for-early-disease-detection 2026-01-12T00:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/5371a1d626524e82/beam-therapeutics-secures-fda-accelerated-approval-pathway-for-beam-302-and-plans-bla-submission-for-risto-cel-by-year-end-2026 2026-01-12T00:15:16+00:00 hourly 0.9 https://trial.medpath.com/news/3ad2ae099f901c8c/teva-and-royalty-pharma-announce-500-million-funding-agreement-for-vitiligo-treatment-tev-408 2026-01-12T00:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/9a16fa430ffd0305/juvena-therapeutics-secures-33-5m-series-b-to-advance-ai-enabled-regenerative-biologics-pipeline 2026-01-12T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/364886a11a0f64d9/benitec-s-bb-301-gene-therapy-shows-sustained-improvement-in-opmd-patients-at-24-month-follow-up 2026-01-11T17:16:15+00:00 hourly 0.9 https://trial.medpath.com/news/9e9e94b6c7d61bc2/carna-health-raises-8-million-to-scale-ai-driven-chronic-kidney-disease-screening-platform-globally 2026-01-11T12:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/751bb86e6598fe99/federal-court-blocks-edwards-lifesciences-jenavalve-acquisition-citing-innovation-harm-in-pre-commercial-tavr-market 2026-01-11T08:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/2a5ae004c48c0541/kinaset-therapeutics-secures-103-million-series-b-to-advance-novel-inhaled-jak-inhibitor-for-severe-asthma 2026-01-11T01:07:43+00:00 hourly 0.9 https://trial.medpath.com/news/5db2abc1e3044c17/neratinib-shows-anti-atherosclerotic-effects-through-novel-ask1-pathway-in-preclinical-studies 2026-01-11T00:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/12ebdccbe5236a1d/medicines360-licenses-novel-stillbirth-risk-assessment-technologies-from-cambridge-and-edinburgh-universities 2026-01-11T00:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/3b1f990b5e8776a8/astrazeneca-completes-phase-1-drug-drug-interaction-study-for-experimental-compound-azd0780-with-metformin 2026-01-10T20:54:38+00:00 hourly 0.9 https://trial.medpath.com/news/65e6e31b11449912/biogen-initiates-phase-1-trial-for-new-skyclarys-tablet-formulation-to-improve-patient-access-in-friedreich-s-ataxia 2026-01-10T20:53:15+00:00 hourly 0.9 https://trial.medpath.com/news/1c9b3f9f9ed758d3/cg-oncology-accelerates-pivot-006-phase-3-timeline-for-bladder-cancer-treatment 2026-01-10T20:51:46+00:00 hourly 0.9 https://trial.medpath.com/news/b82b9fe8f127ea67/etienna-bio-secures-exclusive-license-for-adipose-derived-regenerative-cell-platform-from-umass-chan-medical-school 2026-01-10T20:51:41+00:00 hourly 0.9 https://trial.medpath.com/news/465e896273d7ac8d/lucerastat-demonstrates-significant-efficacy-in-phase-3-trial-for-fabry-disease-treatment 2026-01-10T20:49:52+00:00 hourly 0.9 https://trial.medpath.com/news/f25d351556fa0f65/chinese-researchers-unveil-ai-platform-drugclip-that-accelerates-drug-screening-by-million-fold 2026-01-10T13:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/196f4641e1bf915f/ocugen-s-ocu410st-gene-therapy-shows-54-reduction-in-stargardt-disease-progression-in-phase-1-trial 2026-01-10T12:05:56+00:00 hourly 0.9 https://trial.medpath.com/news/7c2be02350cd2c22/charles-river-laboratories-announces-ceo-succession-plan-as-jim-foster-retires-after-50-year-career 2026-01-10T09:06:58+00:00 hourly 0.9 https://trial.medpath.com/news/c880742d861b7c62/foghorn-therapeutics-secures-50-million-financing-to-advance-first-in-class-cancer-pipeline 2026-01-10T08:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/a9c8fa8269ad5308/imfinzi-shows-survival-benefits-in-small-cell-lung-cancer-but-fails-cost-effectiveness-analysis 2026-01-10T08:07:27+00:00 hourly 0.9 https://trial.medpath.com/news/2b29f429b5b8266f/atezolizumab-plus-bevacizumab-shows-superior-outcomes-compared-to-tace-in-intermediate-stage-hepatocellular-carcinoma 2026-01-10T08:07:25+00:00 hourly 0.9 https://trial.medpath.com/news/c849056cbae05ec1/mindwalk-identifies-universal-functional-constraint-across-influenza-viruses-using-ai-technology 2026-01-10T08:06:27+00:00 hourly 0.9 https://trial.medpath.com/news/7345f33fd9b1c2de/eikon-therapeutics-files-for-100-million-ipo-to-advance-late-stage-cancer-pipeline 2026-01-10T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/1e16a4929682a42e/johnson-johnson-announces-1-billion-cell-therapy-manufacturing-plant-in-pennsylvania 2026-01-10T05:09:52+00:00 hourly 0.9 https://trial.medpath.com/news/a0c0da8e5cbbd194/rolvedon-same-day-dosing-shows-promise-for-breast-cancer-patients-in-phase-1-trial 2026-01-10T01:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/ec4e838f7269b8e6/amarin-reports-strong-q4-2025-performance-as-vascepa-vazkepa-franchise-positioned-to-benefit-from-emerging-triglyceride-therapies 2026-01-10T01:07:16+00:00 hourly 0.9 https://trial.medpath.com/news/55026a2528973d6c/ascendis-pharma-reports-strong-2025-performance-with-eur720m-revenue-and-advances-transcon-pipeline 2026-01-10T01:07:15+00:00 hourly 0.9 https://trial.medpath.com/news/ff3573a5bfca421b/memo-therapeutics-publishes-first-study-mapping-bk-polyomavirus-impact-on-kidney-transplant-recipients-quality-of-life 2026-01-10T00:09:40+00:00 hourly 0.9 https://trial.medpath.com/news/a757e5634560a9f5/haemonetics-acquires-vivasure-medical-for-eur100-million-to-expand-large-bore-vascular-closure-portfolio 2026-01-10T00:07:11+00:00 hourly 0.9 https://trial.medpath.com/news/47f457b452d6bcdf/fda-issues-draft-guidance-on-bayesian-statistical-methods-to-accelerate-clinical-trial-design 2026-01-10T00:07:09+00:00 hourly 0.9 https://trial.medpath.com/news/6506b87d90b0175a/eli-lilly-secures-6-5-billion-houston-manufacturing-plant-with-major-tax-incentives 2026-01-09T23:51:56+00:00 hourly 0.9 https://trial.medpath.com/news/fe67401afd83a861/orca-bio-secures-250m-financing-to-prepare-for-orca-t-commercial-launch-ahead-of-april-2026-fda-decision 2026-01-09T20:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/f2f49ac5c4f48812/scancell-s-dna-immunotherapy-shows-74-progression-free-survival-in-advanced-melanoma-phase-2-trial 2026-01-09T20:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/967708fcc4877e62/marius-pharmaceuticals-initiates-post-marketing-study-of-testosterone-undecanoate-in-men-aged-65-80-with-hypogonadism 2026-01-09T20:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/2e123cbb75cead0a/compass-pathways-and-definium-near-regulatory-milestones-as-psychedelics-field-approaches-commercial-reality 2026-01-09T20:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/00c58807e333b5e2/diamyd-medical-s-type-1-diabetes-immunotherapy-receives-global-non-proprietary-name-retogatein 2026-01-09T20:11:07+00:00 hourly 0.9 https://trial.medpath.com/news/1cecb989196af401/seed-therapeutics-initiates-first-in-human-trial-of-st-01156-novel-molecular-glue-degrader-targeting-rbm39 2026-01-09T20:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/1d4a31ddbaf4c665/bit-bio-secures-50-million-series-c-funding-to-advance-human-cell-programming-technology-for-drug-discovery 2026-01-09T20:09:46+00:00 hourly 0.9 https://trial.medpath.com/news/e78ed9cb6503ad69/transgene-s-tg4050-achieves-100-two-year-disease-free-survival-in-head-and-neck-cancer-phase-i-trial 2026-01-09T20:08:57+00:00 hourly 0.9 https://trial.medpath.com/news/dfa17aaeb2334194/almirall-launches-phase-iii-trial-testing-lebrikizumab-for-nummular-eczema-treatment 2026-01-09T20:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/0cbcd17358c85303/adjuvant-pembrolizumab-fails-to-improve-outcomes-in-hepatocellular-carcinoma-after-curative-treatment 2026-01-09T20:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/97c9636c1a5f5e46/university-of-pennsylvania-biontech-and-oup-launch-50-million-life-sciences-venture-fund 2026-01-09T20:07:57+00:00 hourly 0.9 https://trial.medpath.com/news/de3a35ffd2f0ce33/pfizer-discontinues-mesothelin-targeting-adc-pf-08052666-amid-strategic-pipeline-restructuring 2026-01-09T20:07:33+00:00 hourly 0.9 https://trial.medpath.com/news/e0af313a61de881b/eledon-s-tegoprubart-shows-promise-in-phase-2-kidney-transplant-trial-advances-to-phase-3-development 2026-01-09T19:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/cb5d6b972416f2d8/anika-therapeutics-names-steve-griffin-ceo-as-company-focuses-on-hyaluronic-acid-pipeline 2026-01-09T19:08:42+00:00 hourly 0.9 https://trial.medpath.com/news/3dcbec95bf0081e8/cartesian-therapeutics-advances-car-t-therapy-pipeline-with-fda-approval-for-myositis-trial-and-positive-phase-3-progress 2026-01-09T19:08:23+00:00 hourly 0.9 https://trial.medpath.com/news/86813628462cd026/aptevo-therapeutics-secures-60-million-equity-line-of-credit-to-advance-multispecific-cancer-immunotherapy-pipeline 2026-01-09T19:07:52+00:00 hourly 0.9 https://trial.medpath.com/news/cba39839e2355d89/sparc-restructures-operations-with-10m-cost-savings-target-while-advancing-oncology-and-immunology-pipeline 2026-01-09T19:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/2ceddfa9e207ee2b/bleichroeder-acquisition-corp-ii-completes-287-5m-ipo-targeting-healthcare-technology-disruption 2026-01-09T16:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/dbdb8bf77750f2cb/biocytogen-and-acepodia-expand-partnership-for-next-generation-dual-payload-bispecific-adcs 2026-01-09T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/d6723bd754a09fda/mrna-car-t-cell-therapy-shows-promising-results-for-myasthenia-gravis-in-phase-2b-trial 2026-01-09T16:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/4b521f73fbb56e0f/global-alzheimer-s-platform-foundation-expands-bio-hermes-studies-with-strategic-partnerships 2026-01-09T16:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/294684f0aeed0061/gc-therapeutics-advances-tfometm-platform-with-novel-cell-therapies-for-multiple-sclerosis-and-type-1-diabetes 2026-01-09T16:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/f91bced7ce8b2521/aurobindo-pharma-s-dyrupeg-biosimilar-receives-health-canada-approval-for-cancer-neutropenia-treatment 2026-01-09T16:11:17+00:00 hourly 0.9 https://trial.medpath.com/news/da5d6ac1787d7290/inflarx-cuts-30-of-workforce-deprioritizes-covid-19-therapy-to-focus-on-immunology-pipeline 2026-01-09T16:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/3d3168edc03f4ebd/schrodinger-partners-with-eli-lilly-to-integrate-tunelab-ai-platform-into-livedesign-software 2026-01-09T16:10:28+00:00 hourly 0.9 https://trial.medpath.com/news/b9c0684423373726/cytoreason-expands-ai-driven-drug-discovery-partnership-with-sanofi-in-16-million-multi-year-deal 2026-01-09T16:10:08+00:00 hourly 0.9 https://trial.medpath.com/news/fe90ef72d7932542/airnexis-therapeutics-secures-200m-series-a-to-advance-dual-pde3-4-inhibitor-for-copd-treatment 2026-01-09T16:10:07+00:00 hourly 0.9 https://trial.medpath.com/news/4d4f8857973457e3/enodia-therapeutics-secures-eur20-7m-seed-funding-to-advance-novel-protein-degradation-platform-targeting-sec61-translocon 2026-01-09T16:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/42cc37dae18045b2/ping-an-biomedical-secures-90-million-in-strategic-investments-to-accelerate-biopharmaceutical-innovation 2026-01-09T16:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/8bc17b0fb69c0d43/cellectar-biosciences-advances-iopofosine-i-131-toward-european-approval-for-waldenstrom-s-macroglobulinemia 2026-01-09T16:08:44+00:00 hourly 0.9 https://trial.medpath.com/news/1a97b8e61958bda0/newamsterdam-pharma-advances-obicetrapib-development-with-promising-alzheimer-s-biomarker-data-and-multiple-phase-3-trials 2026-01-09T16:08:38+00:00 hourly 0.9 https://trial.medpath.com/news/54f1521030d7d870/insmed-reports-strong-brinsupri-launch-with-144-6m-first-quarter-revenue-advances-multiple-phase-3-programs 2026-01-09T16:08:37+00:00 hourly 0.9 https://trial.medpath.com/news/7d8845d0db51ca63/soleno-therapeutics-reports-strong-commercial-launch-progress-for-vykat-xr-in-prader-willi-syndrome 2026-01-09T16:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/43803f197141007f/fda-accepts-camurus-resubmitted-nda-for-oclaiz-acromegaly-treatment-with-june-2026-pdufa-date 2026-01-09T16:08:33+00:00 hourly 0.9 https://trial.medpath.com/news/7933b50462486b6c/immunocore-outlines-2026-strategic-priorities-with-focus-on-melanoma-franchise-expansion-and-pipeline-advancement 2026-01-09T15:10:59+00:00 hourly 0.9 https://trial.medpath.com/news/27a1623ba5e45f58/a2-biotherapeutics-receives-fda-clearance-for-a2b543-car-t-therapy-with-il-12-booster-for-advanced-solid-tumors 2026-01-09T15:09:51+00:00 hourly 0.9 https://trial.medpath.com/news/6f27cf43248197e6/liquidia-reports-strong-yutrepia-launch-with-148-3m-in-full-year-2025-sales-expands-clinical-pipeline 2026-01-09T15:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/a60d09692eb97f8a/huons-biopharma-s-hutox-becomes-seventh-botulinum-toxin-approved-in-china-following-nmpa-authorization 2026-01-09T15:07:14+00:00 hourly 0.9 https://trial.medpath.com/news/6780ecf4c472bede/create-medicines-achieves-complete-b-cell-depletion-in-non-human-primates-with-in-vivo-car-t-platform 2026-01-09T09:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/ed621a1dd4967fc6/elephas-biosciences-expands-leadership-and-research-partnerships-to-advance-live-tumor-immunotherapy-platform 2026-01-09T09:02:54+00:00 hourly 0.9 https://trial.medpath.com/news/4f14354459ee99e3/collegium-pharmaceutical-secures-980-million-credit-facility-and-authorizes-generic-nucynta-launch 2026-01-09T09:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/6538de37af9a30d1/mrm-health-receives-fda-ind-clearance-for-phase-2b-trial-of-mh002-live-biotherapeutic-in-ulcerative-colitis 2026-01-09T09:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/23a80e9ba7e7029f/amylyx-advances-amx0318-as-long-acting-glp-1-receptor-antagonist-for-post-bariatric-hypoglycemia 2026-01-09T09:01:59+00:00 hourly 0.9 https://trial.medpath.com/news/0bf22bc8f7b50681/medilink-and-roche-expand-partnership-with-570-million-deal-for-b7h3-targeting-adc-yl201 2026-01-09T05:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/7c717173be7b31fe/entrada-therapeutics-advances-rna-based-pipeline-with-first-ocular-candidate-for-usher-syndrome 2026-01-09T01:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/9009c551ca202719/senseonics-launches-first-commercial-integration-of-one-year-cgm-with-automated-insulin-delivery-system 2026-01-09T01:01:58+00:00 hourly 0.9 https://trial.medpath.com/news/6c05c2316d250b76/mit-engineers-develop-biodegradable-smart-pills-that-report-medication-intake-to-healthcare-providers 2026-01-09T01:01:14+00:00 hourly 0.9 https://trial.medpath.com/news/c2f5b2c8fa055f4d/osel-launches-first-ever-pivotal-trial-of-microbiome-based-cancer-therapy-mo-03-for-advanced-renal-cell-carcinoma 2026-01-09T01:01:13+00:00 hourly 0.9 https://trial.medpath.com/news/b1784a54ec65ff84/acuitas-therapeutics-acquires-majority-stake-in-rna-technologies-therapeutics-to-advance-rna-lnp-therapeutics 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/news/ffbb556b3bc8f9ab/one-genomics-partners-with-cira-foundation-to-advance-high-precision-crispr-technology-for-regenerative-medicine 2026-01-09T00:59:37+00:00 hourly 0.9 https://trial.medpath.com/news/27bad43d0987bfaf/enliven-therapeutics-reports-promising-phase-1b-results-for-elvn-001-in-treatment-resistant-chronic-myeloid-leukemia 2026-01-09T00:59:33+00:00 hourly 0.9 https://trial.medpath.com/news/563a48544456c270/biomarin-and-veeva-systems-expand-strategic-partnership-to-accelerate-rare-disease-drug-development 2026-01-09T00:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/45f612b5a55ace81/tecregen-secures-eur11m-seed-funding-and-appoints-new-ceo-to-advance-thymus-regeneration-therapeutics 2026-01-09T00:59:22+00:00 hourly 0.9 https://trial.medpath.com/news/12a266666fd9ad2c/fda-approves-first-in-class-non-opioid-journavx-for-acute-pain-marking-20-year-breakthrough 2026-01-09T00:58:08+00:00 hourly 0.9 https://trial.medpath.com/news/30b86a79b9d1832f/ubc-researchers-achieve-breakthrough-in-stem-cell-derived-helper-t-cell-production-for-cancer-therapy 2026-01-09T00:58:05+00:00 hourly 0.9 https://trial.medpath.com/news/c530b61995734735/uc-san-diego-researchers-demonstrate-first-successful-personalized-cancer-treatment-based-on-tumor-dna 2026-01-09T00:58:04+00:00 hourly 0.9 https://trial.medpath.com/news/c90057ff9187823c/astrazeneca-names-rick-suarez-us-president-to-lead-50-billion-investment-strategy 2026-01-08T21:13:09+00:00 hourly 0.9 https://trial.medpath.com/news/16eb42d1e2295f10/lonza-s-synaffix-partners-with-sidewinder-therapeutics-to-develop-next-generation-bispecific-adcs-for-solid-tumors 2026-01-08T21:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/616c5ced0f5c2a6c/santhera-secures-swiss-approval-for-agamree-as-nxera-expands-asia-pacific-access-for-duchenne-muscular-dystrophy-treatment 2026-01-08T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/2fe7aa71e551b651/acousia-therapeutics-completes-enrollment-in-phase-2-trial-testing-acou085-for-cisplatin-induced-hearing-loss 2026-01-08T21:11:22+00:00 hourly 0.9 https://trial.medpath.com/news/13aedcb5a584aefd/emergent-biosolutions-partners-with-panther-to-advance-africa-cdc-led-mpox-treatment-trial 2026-01-08T21:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/5893c4ecc4dfbce7/alveus-therapeutics-emerges-with-160m-to-develop-next-generation-obesity-therapies 2026-01-08T21:07:48+00:00 hourly 0.9 https://trial.medpath.com/news/3dc8203141489242/abbelight-secures-series-b-funding-to-expand-super-resolution-microscopy-technology-for-drug-discovery-applications 2026-01-08T21:07:06+00:00 hourly 0.9 https://trial.medpath.com/news/8feacb1cfbc9a327/intent-biologics-receives-fda-fast-track-designation-for-first-in-class-exosome-therapy-for-diabetic-foot-ulcers 2026-01-08T21:07:02+00:00 hourly 0.9 https://trial.medpath.com/news/5e59c1bee608d2de/renexxion-secures-sixth-u-s-patent-for-naronapride-trihydrate-formulation-targeting-multiple-gi-disorders 2026-01-08T21:06:56+00:00 hourly 0.9 https://trial.medpath.com/news/439cf3c7279568f2/candid-therapeutics-advances-t-cell-engagers-to-phase-2-studies-for-autoimmune-diseases 2026-01-08T21:06:53+00:00 hourly 0.9 https://trial.medpath.com/news/1b849b61a868a5a3/mink-therapeutics-launches-phase-1-trial-of-agent-797-for-graft-versus-host-disease-prevention 2026-01-08T21:05:05+00:00 hourly 0.9 https://trial.medpath.com/news/f8e3fdf51d4a3ff8/rani-therapeutics-launches-phase-1-trial-of-oral-glp-1-glp-2-dual-agonist-rt-114-for-obesity-treatment 2026-01-08T21:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/732de2e35e781d34/bullfrog-ai-platform-identifies-pancreatic-cancer-patient-subgroup-with-threefold-survival-improvement 2026-01-08T21:03:33+00:00 hourly 0.9 https://trial.medpath.com/news/611925f32f777255/glycoera-appoints-petra-duda-as-chief-medical-officer-to-lead-precision-protein-degrader-pipeline 2026-01-08T21:02:50+00:00 hourly 0.9 https://trial.medpath.com/news/adc65a1748ae2b7d/zyus-life-sciences-reports-positive-preliminary-results-for-cannabinoid-based-cancer-pain-treatment 2026-01-08T21:00:54+00:00 hourly 0.9 https://trial.medpath.com/news/6d34edda80b17725/lilly-s-combination-therapy-shows-superior-efficacy-in-first-of-kind-trial-for-psoriatic-arthritis-patients-with-obesity 2026-01-08T21:00:23+00:00 hourly 0.9 https://trial.medpath.com/news/de331ee110aa51c8/proqr-reports-positive-phase-1-safety-data-for-rna-editing-therapy-ax-0810-advances-pipeline-programs 2026-01-08T21:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/88fb9d14873f75d0/cormedix-therapeutics-strengthens-leadership-team-with-new-chief-commercial-officer-and-board-restructuring 2026-01-08T21:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/27b4bab0a9dc9145/abbvie-initiates-two-phase-1-trials-expanding-oncology-pipeline-with-abbv-901-and-abbv-243 2026-01-08T21:00:16+00:00 hourly 0.9 https://trial.medpath.com/news/03456a5c8e375fdb/pfizer-partners-with-boltz-to-integrate-ai-models-into-drug-discovery-pipeline 2026-01-08T20:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/51bac9473f95736a/enyo-pharma-s-vonafexor-reverses-kidney-function-decline-in-phase-2-alport-syndrome-trial 2026-01-08T20:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/6244def86b0a7b6c/critics-ii-trial-identifies-optimal-preoperative-strategy-for-resectable-gastric-cancer 2026-01-08T20:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/ee094aea4f148076/varmx-and-rentschler-biopharma-expand-partnership-for-phase-iii-development-of-novel-coagulation-therapy-vmx-c001 2026-01-08T20:59:39+00:00 hourly 0.9 https://trial.medpath.com/news/fbe40395902196d9/nautilus-biotechnology-launches-early-access-program-for-single-molecule-proteomics-platform-with-tau-proteoforms-assay 2026-01-08T20:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/e692566f9c0bc5dd/engitix-secures-eur21-million-series-a-extension-to-advance-ecm-targeted-cancer-and-fibrosis-therapies 2026-01-08T20:59:17+00:00 hourly 0.9 https://trial.medpath.com/news/6d7d8e628543e9ca/oncodesign-precision-medicine-and-ksilink-partner-to-screen-nanocyclix-r-library-for-cns-therapeutics 2026-01-08T20:59:08+00:00 hourly 0.9 https://trial.medpath.com/news/e18074b8460d3f90/fda-grants-fast-track-designation-to-alessa-s-enolen-for-localized-prostate-cancer-treatment 2026-01-08T20:57:56+00:00 hourly 0.9 https://trial.medpath.com/news/64ea5cde9fae337b/annexon-submits-first-ever-targeted-therapy-for-guillain-barre-syndrome-to-european-regulators 2026-01-08T20:57:55+00:00 hourly 0.9 https://trial.medpath.com/news/f35d2264d9ddbb64/yale-study-reveals-gsk3b-inhibitors-as-promising-treatment-for-relapsed-b-cell-acute-lymphoblastic-leukemia 2026-01-08T20:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/0f67d7e4dce484f6/spruce-biosciences-secures-50-million-financing-to-advance-first-potential-treatment-for-sanfilippo-syndrome-type-b 2026-01-08T18:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/c36e6c911f71a1d5/cytomx-advances-masked-adc-varsetatug-masetecan-toward-registrational-trial-in-colorectal-cancer 2026-01-08T18:04:36+00:00 hourly 0.9 https://trial.medpath.com/news/3ae8bcbc3dd9a5ff/ardelyx-reports-strong-2025-performance-with-ibsrela-revenue-growing-73-and-launches-phase-3-trial-for-chronic-constipation 2026-01-08T18:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/e4fbf0429a799f5a/xilio-therapeutics-secures-35-8m-funding-advances-masked-immuno-oncology-pipeline-with-key-development-milestones 2026-01-08T18:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/1fa4bef139fb05d5/parabilis-medicines-secures-305-million-series-f-to-advance-first-in-class-b-catenin-inhibitor-zolucatetide 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/e8787561cdbee9ec/diagonal-therapeutics-secures-125m-series-b-to-advance-first-in-class-clustering-antibody-diag723-for-rare-genetic-diseases 2026-01-08T18:03:54+00:00 hourly 0.9 https://trial.medpath.com/news/91c4c3c27ef9b40b/trevi-therapeutics-advances-haduvio-development-with-fda-end-of-phase-2-meeting-and-phase-2b-trial-plans-for-chronic-cough-treatment 2026-01-08T18:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/b9e991ac652bdfb7/whitehawk-therapeutics-advances-two-next-generation-adcs-into-clinical-trials-with-fda-ind-clearances 2026-01-08T18:03:43+00:00 hourly 0.9 https://trial.medpath.com/news/54fcc0523e7fd3a6/climb-bio-advances-multi-drug-pipeline-with-phase-2-trial-initiation-and-2026-data-readouts-expected 2026-01-08T18:03:17+00:00 hourly 0.9 https://trial.medpath.com/news/458b1b4214364b1a/atsena-therapeutics-completes-phase-i-ii-dosing-for-xlrs-gene-therapy-advances-to-pivotal-trial 2026-01-08T18:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/8034af15b58e8d48/fox-chase-cancer-center-becomes-first-nci-designated-center-to-implement-3d-genome-diagnostics-for-cancer-care 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/010efffb3c2b2ee8/lisata-therapeutics-agrees-to-4-00-per-share-acquisition-by-kuva-labs-in-85-premium-deal 2026-01-08T18:02:34+00:00 hourly 0.9 https://trial.medpath.com/news/9a4086443eed807b/enara-bio-strengthens-dark-antigen-platform-with-expanded-boehringer-partnership-and-new-cmo-ahead-of-ena101-clinical-entry 2026-01-08T18:02:31+00:00 hourly 0.9 https://trial.medpath.com/news/993a7f81215d0bcd/kahr-bio-s-dsp107-shows-promising-17-5-month-survival-in-advanced-colorectal-cancer-phase-2-trial 2026-01-08T18:01:50+00:00 hourly 0.9 https://trial.medpath.com/news/4faecae1b6059108/alveus-therapeutics-raises-160-million-series-a-to-advance-novel-obesity-therapies 2026-01-08T18:01:27+00:00 hourly 0.9 https://trial.medpath.com/news/d6e991fd781ed48c/splicebio-advances-gene-therapy-for-stargardt-disease-with-first-patient-dosed-in-phase-1-2-expansion-trial 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/f5e3c124f5578a2d/lexeo-therapeutics-partners-with-johnson-johnson-to-advance-localized-cardiac-gene-therapy-using-impella-heart-pump-technology 2026-01-08T18:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/d3b80e851625ca53/enanta-pharmaceuticals-advances-rsv-treatment-pipeline-and-expands-immunology-portfolio-with-three-novel-targets 2026-01-08T18:00:04+00:00 hourly 0.9 https://trial.medpath.com/news/724612a71b88f631/enterobiotix-s-ebx-102-02-shows-promise-as-first-in-class-oral-microbiome-therapy-for-irritable-bowel-syndrome 2026-01-08T17:59:54+00:00 hourly 0.9 https://trial.medpath.com/news/992f413543973675/858-therapeutics-receives-fda-fast-track-designation-for-parg-inhibitor-etx-19477-in-brca-mutated-ovarian-cancer 2026-01-08T17:58:57+00:00 hourly 0.9 https://trial.medpath.com/news/7387444a2398e5f5/bamf-health-and-henry-ford-health-partner-to-establish-comprehensive-theranostics-center-in-detroit 2026-01-08T17:58:48+00:00 hourly 0.9 https://trial.medpath.com/news/c1d80c7ab53cdb7b/antin-infrastructure-partners-acquires-clinical-trial-equipment-leader-emsere-in-strategic-healthcare-move 2026-01-08T17:58:26+00:00 hourly 0.9 https://trial.medpath.com/news/e26fe55ec85a829f/just-evotec-biologics-secures-gates-foundation-grant-for-ai-driven-monoclonal-antibody-optimization-to-expand-global-access 2026-01-08T13:00:11+00:00 hourly 0.9 https://trial.medpath.com/news/3a05e46171a2aa57/storm-therapeutics-partners-with-alidabio-to-advance-first-in-class-rna-modifying-enzyme-inhibitor-stc-15 2026-01-08T13:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/bcaaac592d44f7ce/epibiologics-raises-107m-series-b-to-advance-novel-egfr-targeting-bispecific-antibody-epi-326-into-clinical-trials 2026-01-08T13:00:03+00:00 hourly 0.9 https://trial.medpath.com/news/ea92e87ef5700f17/krystal-biotech-to-present-phase-1-data-for-kb407-gene-therapy-in-cystic-fibrosis 2026-01-08T12:59:34+00:00 hourly 0.9 https://trial.medpath.com/news/1cdf60b225edcc4d/hansoh-pharmaceutical-s-aumolertinib-receives-eu-approval-for-advanced-nsclc-treatment 2026-01-08T12:59:29+00:00 hourly 0.9 https://trial.medpath.com/news/5b1d23469661ae27/aboleris-pharma-advances-novel-anti-cd45rc-antibody-abo21009-to-patient-testing-in-rheumatoid-arthritis-phase-1-trial 2026-01-08T12:59:24+00:00 hourly 0.9 https://trial.medpath.com/news/d6021caea50d1308/foresee-pharmaceuticals-licenses-mmp-12-inhibitor-portfolio-to-primevera-therapeutics-in-584-5-million-deal 2026-01-08T12:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/3eaab5b526bc8615/aurora-spine-secures-two-new-u-s-patents-strengthening-spinal-implant-innovation-portfolio 2026-01-08T12:34:00+00:00 hourly 0.9 https://trial.medpath.com/news/c176c746fc028d05/tensive-reports-positive-pivotal-trial-results-for-regeneratm-bioresorbable-breast-reconstruction-device 2026-01-08T10:02:55+00:00 hourly 0.9 https://trial.medpath.com/news/2fd5df80276d268e/ligachem-bioscience-achieves-development-milestone-in-adc-platform-partnership-with-ono-pharmaceutical 2026-01-08T10:01:29+00:00 hourly 0.9 https://trial.medpath.com/news/1f59e900fc111da6/ametris-expands-digital-health-partnerships-with-major-pharmaceutical-companies 2026-01-08T10:01:04+00:00 hourly 0.9 https://trial.medpath.com/news/80ac28cfbcb82c35/pulmocide-terminates-phase-3-trial-of-inhaled-opelconazole-after-interim-analysis-shows-higher-mortality 2026-01-08T10:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/757ea8bca067c8d7/4moving-biotech-secures-fda-ind-clearance-for-first-in-class-intra-articular-glp-1-agonist-in-osteoarthritis 2026-01-08T09:59:52+00:00 hourly 0.9 https://trial.medpath.com/news/e126b38160a84605/neuralight-completes-paloma-study-demonstrating-superior-eye-movement-biomarkers-for-parkinson-s-disease-progression-tracking 2026-01-08T09:59:51+00:00 hourly 0.9 https://trial.medpath.com/news/04dead95d42d1399/spider-venom-derived-drug-ib409-enters-phase-1-clinical-trial-for-heart-attack-and-stroke-treatment 2026-01-08T09:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/6b7586e6ba7db38f/merck-s-ogsiveo-becomes-first-approved-desmoid-tumor-treatment-in-europe 2026-01-08T09:59:44+00:00 hourly 0.9 https://trial.medpath.com/news/7374d1792cc9dec2/antag-therapeutics-reports-promising-phase-1-results-for-novel-gipr-antagonist-at7687-in-obesity-treatment 2026-01-08T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/320eac8738dd1306/ray-therapeutics-strengthens-leadership-team-with-key-executive-appointments-to-advance-optogenetic-vision-therapies 2026-01-08T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/339a7facab2c442d/bighat-biosciences-expands-lilly-partnership-to-develop-ai-powered-antibody-developability-models 2026-01-08T06:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/8174eaeddb125930/mass-general-brigham-s-single-dose-oral-cholera-vaccine-panchol-demonstrates-safety-and-strong-immune-response-in-phase-1-trial 2026-01-08T06:11:35+00:00 hourly 0.9 https://trial.medpath.com/news/1f74ac82f37ad97d/mercy-health-system-joins-major-clinical-study-testing-multi-cancer-blood-screening-in-medicare-population 2026-01-08T04:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/ee01ac36a34e25fb/bambusa-therapeutics-initiates-phase-ib-trial-of-bbt002-bispecific-antibody-for-copd-treatment 2026-01-08T04:12:52+00:00 hourly 0.9 https://trial.medpath.com/news/18319cae8cdff7d6/gland-pharma-receives-fda-approval-for-generic-extra-strength-pataday-eye-allergy-drops 2026-01-08T04:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/3389d0572a063e47/corsera-health-raises-80m-series-a-as-preventative-cardiovascular-sirna-therapy-enters-clinical-testing 2026-01-08T02:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/b030900f4411ae5b/alpha-cognition-launches-real-world-study-for-zunveyl-as-alzheimer-s-drug-gains-commercial-traction 2026-01-08T02:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/3584440430d737e7/prudentia-sciences-raises-20m-series-a-to-transform-life-sciences-due-diligence-with-ai-platform 2026-01-08T02:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/30c2e38d4b3c5219/engineered-bacterial-vesicles-boost-car-t-cell-therapy-effectiveness-against-solid-tumors 2026-01-08T02:18:11+00:00 hourly 0.9 https://trial.medpath.com/news/4215117987bedbbc/pretrm-blood-test-reduces-preterm-birth-complications-in-large-randomized-trial 2026-01-08T02:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/818fa020e8a21214/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/4dceade137ff1555/herantis-pharma-s-her-096-shows-biological-activity-in-parkinson-s-disease-phase-1b-trial 2026-01-08T02:16:09+00:00 hourly 0.9 https://trial.medpath.com/news/694c827ea2b60957/ottimo-pharma-receives-fda-clearance-for-first-in-class-dual-pd-1-vegfr2-antibody-otp-01 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/ff5e6f6ddf7fb7ca/sobi-s-gamifant-shows-promise-in-phase-2a-trial-for-interferon-gamma-driven-sepsis 2026-01-08T02:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/13139f17e1b4a6c1/deepseq-ai-secures-investment-from-zaka-vc-to-advance-ai-driven-protein-drug-discovery-platform 2026-01-08T02:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/1bef2d6ae7aa0188/arbele-s-arb1002-receives-fda-orphan-drug-designation-for-pancreatic-cancer-treatment 2026-01-08T02:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/a49c9dc1e3d47e1f/avance-clinical-acquires-lumabridge-to-establish-global-oncology-center-of-excellence 2026-01-08T02:15:09+00:00 hourly 0.9 https://trial.medpath.com/news/8d8ff3a35539dbdd/elevatebio-reports-sixth-consecutive-year-of-revenue-growth-with-98-manufacturing-success-rate 2026-01-08T02:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/72e5a281be180db2/glp-1-receptor-agonists-reduce-asthma-exacerbations-by-49-in-adolescents-with-obesity 2026-01-08T02:08:56+00:00 hourly 0.9 https://trial.medpath.com/news/c98e2a25a2e5a9db/johnson-johnson-submits-ottava-robotic-surgical-system-to-fda-for-de-novo-classification 2026-01-08T02:08:55+00:00 hourly 0.9 https://trial.medpath.com/news/3dac58869a82ce05/verrica-pharmaceuticals-initiates-phase-3-trial-for-vp-102-in-common-warts-treatment 2026-01-08T02:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/3119cae1549aaedf/varsity-healthcare-partners-invests-in-trialbee-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:52+00:00 hourly 0.9 https://trial.medpath.com/news/1e2c86408ed35e96/trialbee-secures-majority-investment-from-varsity-healthcare-partners-to-accelerate-clinical-trial-patient-recruitment 2026-01-08T02:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/c9d0e16c594776a1/pharmaceutical-companies-seek-direct-deals-with-trump-administration-to-avoid-pricing-penalties 2026-01-08T02:08:28+00:00 hourly 0.9 https://trial.medpath.com/news/98f33fb1b58cfa40/volastra-therapeutics-expands-kif18a-inhibitor-program-following-positive-clinical-data 2026-01-08T02:08:11+00:00 hourly 0.9 https://trial.medpath.com/news/1cf5c7c940028350/ovation-science-secures-canadian-patent-for-enhanced-cannabinoid-transdermal-delivery-technology 2026-01-08T02:06:02+00:00 hourly 0.9 https://trial.medpath.com/news/7af03b8ea63ecdee/solvonis-therapeutics-svn-15-matches-prozac-efficacy-in-depression-model-targets-dual-serotonin-dopamine-pathway 2026-01-08T02:06:01+00:00 hourly 0.9 https://trial.medpath.com/news/bfb5eea71818b669/lift-biosciences-appoints-new-ceo-as-company-prepares-for-phase-1-trial-of-novel-neutrophil-based-cancer-immunotherapy 2026-01-08T02:05:21+00:00 hourly 0.9 https://trial.medpath.com/news/f9f4fc4f818d964f/luminate-secures-21-million-series-a-to-advance-home-based-cancer-treatment-technology 2026-01-08T02:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/5a4501eb553067e8/monte-rosa-s-mrt-8102-demonstrates-85-reduction-in-cardiovascular-inflammation-marker-in-phase-1-trial 2026-01-08T02:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/e77b513e0a3a537b/mediar-therapeutics-secures-76-million-series-b-to-advance-first-in-class-anti-fibrotic-pipeline 2026-01-08T02:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/b475168c45a05779/inimmune-launches-pivotal-phase-2-trial-of-ini-2004-for-allergic-rhinitis-treatment 2026-01-08T02:04:11+00:00 hourly 0.9 https://trial.medpath.com/news/bd12f1801a17b9c6/curium-receives-chinese-regulatory-approval-to-begin-phase-3-trial-of-177lu-psma-i-t-for-metastatic-prostate-cancer 2026-01-08T02:04:07+00:00 hourly 0.9 https://trial.medpath.com/news/dfb67f89a44d4770/adicet-bio-advances-gamma-delta-t-cell-therapy-pipeline-with-fda-alignment-and-2026-milestones 2026-01-08T02:00:26+00:00 hourly 0.9 https://trial.medpath.com/news/f14269f52643c239/fibrogen-rebrands-as-kyntra-bio-advances-cd46-targeting-adc-and-roxadustat-programs 2026-01-08T02:00:25+00:00 hourly 0.9 https://trial.medpath.com/news/deb7c8bdc11541cd/fda-and-ema-grant-orphan-drug-designation-to-cpi-008-for-pancreatic-cancer-surgical-imaging 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/news/8f77d7118235bf13/realta-life-sciences-appoints-biotech-veteran-jonathan-rigby-to-board-as-company-advances-inflammation-targeting-pipeline 2026-01-08T01:59:50+00:00 hourly 0.9 https://trial.medpath.com/news/034720b31b628f05/immunic-completes-phase-3-enrollment-for-multiple-sclerosis-drug-reports-positive-progressive-ms-data 2026-01-08T01:59:48+00:00 hourly 0.9 https://trial.medpath.com/news/5cec951971764ecb/evogene-and-unravel-biosciences-partner-to-develop-first-in-class-remyelination-therapy-for-multiple-sclerosis 2026-01-08T01:59:38+00:00 hourly 0.9 https://trial.medpath.com/news/5fdf9220271148d8/headlamp-health-launches-lumos-ai-platform-to-transform-neuroscience-drug-development 2026-01-08T01:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/4c2b989cea817292/merck-launches-phase-3-kandlelit-007-trial-for-calderasib-keytruda-qlex-combination-in-kras-g12c-mutant-lung-cancer 2026-01-08T01:59:23+00:00 hourly 0.9 https://trial.medpath.com/news/4eb3e0b60116d015/gsk-partners-with-helix-in-multi-year-precision-medicine-collaboration-to-accelerate-drug-development 2026-01-08T01:59:19+00:00 hourly 0.9 https://trial.medpath.com/news/d67bb55578443b64/fda-accepts-comp360-psilocybin-ind-application-for-ptsd-treatment-as-compass-pathways-advances-late-stage-clinical-development 2026-01-08T01:57:55+00:00 hourly 0.9 https://trial.medpath.com/news/9a10abfc87cc1462/rakuten-medical-secures-100-million-series-f-to-advance-asp-1929-toward-u-s-approval 2026-01-08T01:57:45+00:00 hourly 0.9 https://trial.medpath.com/news/783840cd87bb44cf/bioxcel-therapeutics-to-submit-snda-for-at-home-use-of-igalmi-in-agitation-treatment 2026-01-08T01:57:44+00:00 hourly 0.9 https://trial.medpath.com/news/b698c2926146be3b/caredx-and-10x-genomics-launch-immunescape-program-to-decode-transplant-rejection-using-multiomics-technology 2026-01-08T01:57:18+00:00 hourly 0.9 https://trial.medpath.com/news/5d1af85e93433baf/syndax-partners-with-woda-to-expand-global-access-to-revuforj-through-multi-regional-managed-access-program 2026-01-08T01:57:17+00:00 hourly 0.9 https://trial.medpath.com/news/715b16eb02a3a084/silybin-carvedilol-combination-shows-synergistic-effects-against-liver-fibrosis-in-preclinical-studies 2026-01-08T01:57:07+00:00 hourly 0.9 https://trial.medpath.com/news/a2e0d16eed215c2e/stallergenes-greer-acquires-entomon-to-strengthen-venom-immunotherapy-supply-chain 2026-01-08T01:55:41+00:00 hourly 0.9 https://trial.medpath.com/news/5bb9a0b81f10db9b/scenic-biotech-partners-with-ono-pharmaceutical-to-advance-novel-target-discovery-using-cell-seq-platform 2026-01-08T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/a7a763d6d563881e/gsk-s-bepirovirsen-achieves-breakthrough-functional-cure-rates-in-phase-iii-chronic-hepatitis-b-trials 2026-01-08T01:52:58+00:00 hourly 0.9 https://trial.medpath.com/news/c603167212fa8543/neurosterix-initiates-phase-1-trial-of-ntx-253-novel-m4-receptor-modulator-for-schizophrenia-treatment 2026-01-08T01:51:52+00:00 hourly 0.9 https://trial.medpath.com/news/dee44368cf71328a/gsk-s-experimental-hepatitis-b-drug-bepirovirsen-achieves-functional-cure-in-pivotal-studies 2026-01-08T01:51:45+00:00 hourly 0.9 https://trial.medpath.com/news/46272711f6d2be9c/jjp-biologics-reports-positive-phase-i-results-for-first-in-class-anti-cd89-antibody-jjp-1212 2026-01-08T01:51:22+00:00 hourly 0.9 https://trial.medpath.com/news/7218ff430eca878c/merck-pursues-acquisition-of-cancer-drug-developer-revolution-medicines 2026-01-08T01:51:21+00:00 hourly 0.9 https://trial.medpath.com/news/f4d43f7de0c460b9/cvrx-launches-benefit-hf-trial-to-evaluate-barostim-therapy-in-expanded-heart-failure-population 2026-01-08T01:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/23bf41b06af912a4/ascentage-pharma-receives-fda-clearance-for-novel-btk-protein-degrader-apg-3288-in-b-cell-malignancies 2026-01-08T01:48:23+00:00 hourly 0.9 https://trial.medpath.com/news/9f53f743817f51ed/arcutis-projects-455-470m-zoryve-revenue-for-2026-as-dermatology-portfolio-expands 2026-01-08T01:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/baeadb30799e2272/hutchmed-s-sovleplenib-meets-primary-endpoint-in-phase-iii-trial-for-warm-autoimmune-hemolytic-anemia 2026-01-08T01:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/fdbd9e42a3bffeba/healthbiome-achieves-dual-regulatory-approval-for-akkermansia-based-muscle-health-ingredient 2026-01-08T01:47:48+00:00 hourly 0.9 https://trial.medpath.com/news/885c019304efb054/bayer-sues-major-covid-19-vaccine-makers-over-alleged-mrna-technology-patent-infringement 2026-01-08T01:44:29+00:00 hourly 0.9 https://trial.medpath.com/news/93a8209dd0b68310/bayer-expands-genetic-medicine-portfolio-through-strategic-sirna-and-ai-partnerships 2026-01-08T01:44:27+00:00 hourly 0.9 https://trial.medpath.com/news/7e712f0721099e7f/picard-medical-launches-fda-cleared-connector-covers-for-syncardia-total-artificial-heart 2026-01-08T01:44:21+00:00 hourly 0.9 https://trial.medpath.com/news/0ca885530958415a/nucana-appoints-theresa-bruce-as-coo-to-advance-cancer-drug-pipeline 2026-01-08T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/b75bfff4017dc42a/dem-biopharma-to-present-first-in-class-adc-dem301-for-gastrointestinal-cancers-at-asco-gi-2026 2026-01-08T01:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/14fa86b4c6ba040a/two-novel-parkinson-s-therapies-advance-to-late-stage-clinical-trials 2026-01-08T01:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/52f7b12cb76c08ae/instil-bio-terminates-licensing-agreement-and-discontinues-lead-cancer-drug-development 2026-01-08T01:41:58+00:00 hourly 0.9 https://trial.medpath.com/news/0db07b000daced30/exvade-bioscience-enrolls-first-patients-in-revolutionary-glioblastoma-trial-using-fda-breakthrough-tumor-monorail-device 2026-01-08T01:39:06+00:00 hourly 0.9 https://trial.medpath.com/news/9fd347ab14803bcc/sparrow-pharmaceuticals-initiates-phase-2b-trial-of-clofutriben-for-difficult-to-control-type-2-diabetes 2026-01-08T01:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/ce90eb75eaed29de/mdxhealth-partners-with-oxford-to-validate-genomic-prostate-score-in-landmark-protect-trial 2026-01-08T01:35:48+00:00 hourly 0.9 https://trial.medpath.com/news/fd950f3f3de91976/trump-administration-cuts-childhood-vaccine-schedule-from-17-to-11-diseases-impacting-major-vaccine-manufacturers 2026-01-08T01:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/97da70ad197d6239/novoron-bioscience-secures-2-5m-nih-grant-to-advance-human-brain-organoid-platform-for-alzheimer-s-drug-discovery 2026-01-08T01:32:57+00:00 hourly 0.9 https://trial.medpath.com/news/87657eee2b0cbbb1/legacy-healthcare-receives-fda-clearance-to-advance-botanical-drug-cinainu-into-phase-3-trial-for-alopecia-areata 2026-01-08T01:32:55+00:00 hourly 0.9 https://trial.medpath.com/news/05fb6f07aea90707/vivavision-biotech-receives-fda-approval-for-streamlined-vvn461hd-development-path-in-non-infectious-anterior-uveitis 2026-01-08T01:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/2666d786ea6b42e1/baird-medical-expands-global-microwave-ablation-technology-footprint-with-new-market-launches 2026-01-07T13:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/c44cf09c7e9963d9/alloy-therapeutics-names-christian-cobaugh-ceo-of-genetic-medicines-division-to-advance-anticlastic-rna-platform 2026-01-07T09:33:41+00:00 hourly 0.9 https://trial.medpath.com/news/6aa441b87e1a9356/arrowhead-s-gene-silencing-drugs-show-promise-in-early-obesity-studies-enhancing-weight-loss-when-combined-with-zepbound 2026-01-07T09:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/f8d8699b3c7e547f/seres-therapeutics-publishes-mechanism-data-for-vowst-in-nature-medicine-validates-live-biotherapeutics-platform 2026-01-07T09:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/7677fec28ecebdb1/three-biotech-companies-secure-international-funding-for-next-generation-genetic-medicine-platform 2026-01-07T09:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/8d8d029b96258743/amgen-acquires-dark-blue-therapeutics-for-up-to-840-million-to-advance-acute-leukemia-pipeline 2026-01-07T09:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/7c4e62b6ebc2177d/roche-secures-patent-license-for-obesity-drug-ct-996-in-100-million-deal-with-structure-therapeutics 2026-01-07T09:30:27+00:00 hourly 0.9 https://trial.medpath.com/news/9a06cc4b85eb654d/3t-biosciences-strengthens-leadership-with-key-appointments-to-advance-solid-tumor-immunotherapy-pipeline 2026-01-07T09:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/9487db5eda6942fb/kincell-bio-appoints-industry-veteran-larry-pitcher-as-ceo-to-drive-cell-therapy-manufacturing-expansion 2026-01-07T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/26fd675728c00db0/aclaris-therapeutics-reports-positive-phase-1a-results-for-bispecific-antibody-ati-052-accelerating-development-timeline 2026-01-07T09:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/ed265b46b6b4a7a7/ibex-medical-analytics-expands-ai-powered-pathology-platform-to-support-early-stage-drug-development 2026-01-07T09:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/c6addb8d9f074c38/pridcor-therapeutics-advances-long-covid-treatment-with-peer-reviewed-publication-and-fda-ind-exemption-for-phase-2-shield-study 2026-01-07T09:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/7924c0e67167ce8e/bactolife-raises-eur30-million-series-b-to-commercialize-gut-health-binding-proteins-technology 2026-01-07T09:28:29+00:00 hourly 0.9 https://trial.medpath.com/news/4687e54a00e2721a/health-canada-approves-maviret-as-first-eight-week-treatment-for-acute-hepatitis-c 2026-01-07T09:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/b41650c9aed75418/injectable-skin-derived-paste-shows-promise-for-breast-reconstruction-after-cancer-surgery 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/05bef7a02eeadb00/eg-427-s-dna-therapy-eg110a-maintains-88-reduction-in-neurogenic-bladder-incontinence-at-24-weeks 2026-01-07T09:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/4aa7975eb5d50d19/alvotech-announces-ceo-succession-as-lisa-graver-takes-leadership-of-biosimilar-company 2026-01-07T09:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/27f479846ef57064/johnson-johnson-s-nipocalimab-achieves-first-positive-phase-2-results-for-systemic-lupus-erythematosus-treatment 2026-01-07T09:27:22+00:00 hourly 0.9 https://trial.medpath.com/news/b076108f89e06162/stealth-biotherapeutics-advances-first-fda-approved-mitochondrial-therapy-forzinity-for-barth-syndrome 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/06f0168ffd35456c/genprex-s-gene-therapy-gpx-002-shows-promise-in-type-2-diabetes-animal-studies 2026-01-07T09:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/4c277b4550b5ff34/biomendics-advances-first-in-class-therapy-for-epidermolysis-bullosa-simplex-with-tames-02-trial 2026-01-07T09:27:15+00:00 hourly 0.9 https://trial.medpath.com/news/5207bdd9b6dc8d2f/zentalis-advances-azenosertib-toward-potential-accelerated-approval-with-key-2026-milestones-in-ovarian-cancer 2026-01-07T09:27:08+00:00 hourly 0.9 https://trial.medpath.com/news/522bf166632835a4/galecto-strengthens-leadership-team-with-blueprint-medicines-veterans-as-dmr-001-advances-toward-clinical-trials 2026-01-07T09:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/cef3da80d0736ca0/gilead-partners-with-onconano-medicine-in-300m-drug-delivery-collaboration-for-cancer-therapeutics 2026-01-07T09:26:38+00:00 hourly 0.9 https://trial.medpath.com/news/555f9a9079f2b6dc/vividion-s-wrn-inhibitor-vvd-214-shows-promise-for-msi-high-cancers-in-journal-of-medicinal-chemistry-publication 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/6f09e59809ca1177/bostongene-and-astrazeneca-partner-to-deploy-ai-foundation-model-for-precision-oncology-development 2026-01-07T09:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/7ae0803bdbeb45cf/regentis-gelrinc-demonstrates-near-complete-cartilage-repair-in-24-month-phase-ii-study-using-quantitative-mocart-assessment 2026-01-07T09:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/7190da97ef61b5fa/akebia-therapeutics-initiates-phase-2-trial-of-praliciguat-for-rare-kidney-disease-fsgs 2026-01-07T09:26:24+00:00 hourly 0.9 https://trial.medpath.com/news/25431854e15c51a0/transcelerate-study-reveals-one-third-of-clinical-trial-procedures-are-non-essential-proposes-streamlined-data-collection-framework 2026-01-07T09:26:20+00:00 hourly 0.9 https://trial.medpath.com/news/c95280f9b1d2444e/fda-approves-first-venous-stent-for-deep-venous-disease-in-ivc-and-iliofemoral-veins 2026-01-07T09:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/a499fcbafb7231bd/loqus23-advances-first-in-class-oral-drug-lqt-23-for-huntington-s-disease-treatment 2026-01-07T09:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/1bb61b11901b240a/billiontoone-s-northstar-select-liquid-biopsy-selected-for-major-japanese-lung-cancer-resistance-study 2026-01-07T09:26:07+00:00 hourly 0.9 https://trial.medpath.com/news/ebd7154c4e63f607/amgen-acquires-dark-blue-therapeutics-for-840-million-to-advance-aml-treatment 2026-01-07T09:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/6281651e42985c6f/uk-italy-consortium-launches-ps3m-study-to-define-true-remission-in-inflammatory-arthritis 2026-01-07T09:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/ce1a4eb6ac63a6af/variant-bio-launches-world-s-first-agentic-ai-platform-for-genomic-drug-discovery 2026-01-07T09:25:29+00:00 hourly 0.9 https://trial.medpath.com/news/308e75eee531b96d/iavi-initiates-phase-1-trial-of-novel-mrna-hiv-vaccine-targeting-broadly-neutralizing-antibodies 2026-01-07T09:25:26+00:00 hourly 0.9 https://trial.medpath.com/news/9ac0af25c0583e28/nanomosaic-appoints-dr-anne-marie-morse-to-lead-clinical-advisory-board-for-ultra-sensitive-diagnostic-platform 2026-01-07T09:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/cc5376ff2901c33e/biosplice-submits-first-potential-disease-modifying-osteoarthritis-drug-to-fda 2026-01-07T09:24:12+00:00 hourly 0.9 https://trial.medpath.com/news/4e54ffa7397e12a9/aclarion-advances-clarity-trial-enrollment-with-northwestern-medicine-and-scripps-health-participation 2026-01-07T09:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/8b3d6624720d1436/apogee-s-zumilokibart-shows-promising-results-in-phase-1b-asthma-trial-with-durable-biomarker-suppression 2026-01-07T09:23:47+00:00 hourly 0.9 https://trial.medpath.com/news/20fba05de5a38587/leon-s-fr-jet-technology-enables-high-concentration-mrna-lnp-manufacturing-with-enhanced-in-vivo-activity 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/182e0a19bd713709/cyclerion-therapeutics-partners-with-medsteer-to-advance-cyc-126-for-treatment-resistant-depression 2026-01-07T09:23:17+00:00 hourly 0.9 https://trial.medpath.com/news/492e2451d266d03a/oxford-initiates-european-enrollment-for-fortify-trial-testing-orticumab-in-post-heart-attack-inflammation 2026-01-07T09:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/bf999d3f53773d03/hummingbird-bioscience-doses-first-patient-in-phase-i-trial-of-her3-targeted-adc-hmbd-501 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/88c5f2509971661d/acesion-pharma-initiates-phase-2-trial-of-first-in-class-sk-ion-channel-inhibitor-ap31969-for-atrial-fibrillation 2026-01-07T09:22:47+00:00 hourly 0.9 https://trial.medpath.com/news/5bc058abc53dbd18/ikarovec-secures-exclusive-option-for-vectorbuilder-s-novel-aav-capsid-technology-in-1b-deal-for-amd-gene-therapy 2026-01-07T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/15337640cafeab55/gccl-expands-global-clinical-trial-network-through-strategic-partnerships-with-opis-and-medicover 2026-01-07T06:10:03+00:00 hourly 0.9 https://trial.medpath.com/news/33906c70d09de656/saga-diagnostics-expands-ultrasensitive-pathlight-mrd-test-to-colorectal-cancer-following-strong-citcca-study-results 2026-01-07T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/05ddd68664379c7c/waters-corporation-shareholders-approve-17-5-billion-merger-with-bd-biosciences-transaction-set-to-close-february-2026 2026-01-06T17:48:00+00:00 hourly 0.9 https://trial.medpath.com/news/2e6291d1ad61b5cb/china-approves-azstarys-for-adhd-treatment-offering-first-dual-mechanism-therapy-for-23-million-affected-patients 2026-01-06T10:00:34+00:00 hourly 0.9 https://trial.medpath.com/news/cd1647b9327af796/bright-minds-biosciences-set-to-release-phase-2-results-for-bmb-101-in-drug-resistant-epilepsy 2026-01-06T10:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/c3777bbec35d2c03/transpire-bio-achieves-first-human-dosing-milestone-for-novel-cns-inhalation-therapy 2026-01-06T07:01:00+00:00 hourly 0.9 https://trial.medpath.com/news/0bc9d9ac7bfebba9/gut-bacteria-derived-molecule-doubles-lung-cancer-immunotherapy-response-in-preclinical-study 2026-01-06T05:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/23e33ec13f49b65e/sisram-medical-s-daxxify-clears-final-regulatory-hurdle-for-china-market-launch 2026-01-06T03:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/2269b867b8aa35b5/alumis-to-report-phase-3-onward-topline-data-for-envudeucitinib-in-moderate-to-severe-plaque-psoriasis 2026-01-06T03:19:28+00:00 hourly 0.9 https://trial.medpath.com/news/6851136ac967ef13/in-vivo-car-t-therapy-gains-momentum-with-four-new-clinical-programs-entering-phase-1-studies 2026-01-06T00:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/d190e144081359d1/arrowhead-pharmaceuticals-raises-700-million-to-advance-rnai-therapeutics-pipeline 2026-01-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7c06e25629acce80/indiana-attorney-general-sues-eli-lilly-over-alleged-insulin-price-manipulation 2026-01-05T21:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/fbea0d8f1366aec9/decipher-genomic-classifier-shows-promise-for-predicting-prostate-cancer-treatment-outcomes 2026-01-05T21:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/a6104f449f8e7333/incyte-reports-strong-q4-revenue-growth-of-28-driven-by-jakafi-and-opzelura-performance 2026-01-05T21:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/7c90c11f8bf8f790/genelux-reports-promising-early-results-for-olvi-vec-in-advanced-lung-cancer-trials 2026-01-05T20:19:26+00:00 hourly 0.9 https://trial.medpath.com/news/d10c9055389efebb/cornell-developed-silica-nanoparticles-transform-cold-tumors-to-enhance-immunotherapy-response 2026-01-05T20:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/ae4be2cd9d3045a2/halozyme-expands-enhanze-technology-through-strategic-partnerships-with-takeda-and-skye-bioscience 2026-01-05T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/933d0fdca02a490c/nrx-pharmaceuticals-and-neurocare-group-partner-to-create-nationwide-neuroplastic-therapy-network-for-depression-and-ptsd 2026-01-05T17:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/89dca504edc6ecdb/neumora-s-nmra-511-shows-clinically-meaningful-results-in-phase-1b-alzheimer-s-agitation-study 2026-01-05T17:31:05+00:00 hourly 0.9 https://trial.medpath.com/news/516771c1254d98f4/tango-therapeutics-names-new-ceo-as-vopimetostat-advances-to-pivotal-studies 2026-01-05T17:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/077fd92435db4b8e/coherus-oncology-publishes-promising-data-on-ccr8-targeting-antibody-tagmokitug-for-solid-tumors 2026-01-05T17:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/a315f18dbf928511/ai-driven-analysis-identifies-two-new-multiple-sclerosis-subtypes-advancing-precision-medicine-approaches 2026-01-05T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/50fc09012c8eef4d/major-leucovorin-autism-study-retracted-due-to-data-issues-as-largest-trial-approaches-2026-results 2026-01-05T17:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/0d86ae67df9f9b11/multi-antigen-t-cell-therapy-shows-84-6-disease-control-rate-in-pancreatic-cancer-phase-1-2-trial 2026-01-05T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/b14555a882744d03/okyo-pharma-appoints-ophthalmology-veteran-robert-dempsey-as-ceo-to-advance-neuropathic-corneal-pain-treatment 2026-01-05T17:20:53+00:00 hourly 0.9 https://trial.medpath.com/news/e4deb0229fb35899/soleno-therapeutics-publishes-pivotal-vykat-xr-study-results-in-leading-endocrinology-journal 2026-01-05T17:20:47+00:00 hourly 0.9 https://trial.medpath.com/news/7ca54fa0378ab2b7/civicascript-launches-low-cost-insulin-biosimilar-and-ustekinumab-alternative-in-us-market 2026-01-05T17:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/45e6a0f43872f8c8/neumora-therapeutics-outlines-2026-pipeline-strategy-with-multiple-clinical-readouts-expected 2026-01-05T17:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/872d9e606515d7a9/nanoscope-therapeutics-advances-optogenetic-therapy-with-rolling-bla-submission-and-expansion-plans 2026-01-05T17:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/152cdfa069bf8b43/compass-therapeutics-strengthens-leadership-team-with-experienced-oncology-executives 2026-01-05T17:20:36+00:00 hourly 0.9 https://trial.medpath.com/news/e033961055a593a9/nanjing-delova-s-qp-6211-achieves-primary-endpoints-in-phase-3-trials-for-postoperative-pain-management 2026-01-05T17:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/5afbe879b860a22d/bd-achieves-first-prophylactic-hernia-prevention-case-in-europe-with-phasix-mesh-as-prevent-trial-nears-completion 2026-01-05T17:19:37+00:00 hourly 0.9 https://trial.medpath.com/news/3aef01733ff76db2/three-novel-anxiety-medications-advance-toward-2026-fda-review-marking-first-major-breakthrough-in-over-a-decade 2026-01-05T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/48413107c8530e54/redhill-advances-rhb-102-for-glp-1-therapy-side-effects-as-market-faces-35-billion-loss-risk 2026-01-05T16:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/bbf278e85cf06c44/angitia-biopharmaceuticals-completes-enrollment-in-phase-2-trial-of-dual-target-osteoporosis-therapy-aga2118 2026-01-05T16:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/8f79227e02649893/fda-grants-breakthrough-therapy-and-fast-track-designations-to-protara-s-tara-002-for-pediatric-lymphatic-malformations 2026-01-05T16:20:08+00:00 hourly 0.9 https://trial.medpath.com/news/c72b31f3c521d601/gyre-therapeutics-secures-conditional-approval-pathway-for-hydronidone-in-china-following-successful-phase-3-trial 2026-01-05T16:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/c766be695f803b00/maplight-therapeutics-receives-fda-fast-track-designation-for-alzheimer-s-disease-psychosis-treatment 2026-01-05T16:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/795333751d20199e/comprehensive-analysis-reveals-1221-precision-medicine-deals-worth-billions-since-2019 2026-01-05T16:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/4dbbe38e1c33bd9c/stimlabs-launches-first-fda-cleared-human-umbilical-cord-particulate-device-for-wound-management 2026-01-05T16:18:52+00:00 hourly 0.9 https://trial.medpath.com/news/94c5ea20eb443cc0/synusight-abli-therapeutics-and-xingimaging-partner-to-advance-alpha-synuclein-pet-imaging-in-parkinson-s-disease-trials 2026-01-05T16:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/3b74943f5b9d0f38/metavia-s-da-1726-demonstrates-9-1-weight-loss-and-significant-metabolic-benefits-in-phase-1b-obesity-trial 2026-01-05T16:18:39+00:00 hourly 0.9 https://trial.medpath.com/news/7e1a25678a2eb7ba/fda-approves-first-generic-pergolide-tablets-for-equine-cushing-disease-treatment 2026-01-05T16:18:19+00:00 hourly 0.9 https://trial.medpath.com/news/cc9b9eff6115ceab/jade-biosciences-advances-three-monoclonal-antibody-programs-for-autoimmune-diseases-with-phase-1-data-expected-in-2026 2026-01-05T13:19:12+00:00 hourly 0.9 https://trial.medpath.com/news/3f0c4e13b6f463cf/argenx-announces-leadership-transition-as-karen-massey-set-to-replace-tim-van-hauwermeiren-as-ceo 2026-01-05T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/b083cd33858ba1cb/compass-therapeutics-advances-multiple-bispecific-antibody-programs-with-key-biliary-tract-cancer-data-expected-q1-2026 2026-01-05T13:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/7571410de6f261e1/oral-htt-lowering-drug-branaplam-shows-promise-but-halted-due-to-peripheral-neuropathy-in-phase-2-huntington-s-disease-trial 2026-01-05T13:18:02+00:00 hourly 0.9 https://trial.medpath.com/news/63b83127ff429997/megestrol-acetate-shows-dual-benefits-in-er-positive-breast-cancer-treatment 2026-01-05T13:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/577fd555080fb35d/earendil-labs-partners-with-sanofi-in-2-56-billion-ai-driven-bispecific-antibody-collaboration-for-autoimmune-diseases 2026-01-05T13:17:06+00:00 hourly 0.9 https://trial.medpath.com/news/9b43b1af08cb1b69/alcanza-clinical-research-expands-network-through-strategic-acquisition-of-tampa-bay-medical-research 2026-01-05T12:17:12+00:00 hourly 0.9 https://trial.medpath.com/news/4bd316947c15e2ee/scinopharm-becomes-first-taiwan-company-to-win-fda-approval-for-complex-multiple-sclerosis-treatment 2026-01-05T09:26:41+00:00 hourly 0.9 https://trial.medpath.com/news/a90d5c7447732ce8/bioinvent-s-bi-1808-plus-pembrolizumab-shows-24-response-rate-in-recurrent-ovarian-cancer 2026-01-05T08:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/b38c4f0317b16c20/kaist-develops-ai-platform-for-b-cell-reactive-cancer-vaccines-plans-2027-clinical-trials 2026-01-05T08:41:34+00:00 hourly 0.9 https://trial.medpath.com/news/3cb2a70d147af95a/geneditbio-receives-fda-clearance-for-first-in-class-crispr-gene-therapy-trial-in-tgfbi-corneal-dystrophy 2026-01-05T08:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/02df9aaae493f071/orum-therapeutics-appoints-chad-may-as-chief-scientific-officer-to-advance-degrader-antibody-conjugate-platform 2026-01-05T06:39:21+00:00 hourly 0.9 https://trial.medpath.com/news/cc8b997229580422/car-t-cell-therapy-shows-promise-for-rejuvenating-aging-intestines-in-preclinical-study 2026-01-05T06:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/ae90bed10d9b5674/stereotactic-body-radiotherapy-shows-promise-for-oligometastatic-cancer-treatment-without-systemic-therapy 2026-01-05T06:36:59+00:00 hourly 0.9 https://trial.medpath.com/news/b33017343f27df98/datasea-partners-with-chinese-bci-company-to-advance-acoustic-enhanced-brain-computer-interface-technology 2026-01-04T23:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/167262df7b4c6e10/south-korean-biopharma-sector-gains-global-momentum-with-4-2-billion-in-licensing-deals 2026-01-04T13:25:40+00:00 hourly 0.9 https://trial.medpath.com/news/22ac2c790918075c/novel-microneedle-patch-combines-zerumbone-and-icg-for-dual-mode-melanoma-therapy 2026-01-04T13:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/f12c092c7f1b1c9a/beaver-trial-demonstrates-efficacy-of-binimetinib-encorafenib-combination-in-advanced-non-v600e-braf-mutated-tumors 2026-01-04T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/9af0f28e4fbec186/novel-cancer-vaccine-using-blood-cleaning-technology-enters-phase-1-trial-for-ovarian-cancer 2026-01-04T06:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/cb6706bab1ff218a/plant-derived-extracellular-vesicles-enable-itraconazole-delivery-across-blood-brain-barrier-for-glioblastoma-treatment 2026-01-04T05:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/2d92ed58d8495aa0/neuralink-expands-human-trials-to-21-participants-as-musk-announces-next-generation-brain-implant 2026-01-04T04:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/5591139d816361a7/lipid-nanoparticles-enable-durable-crispr-gene-editing-in-muscle-stem-cells-for-duchenne-muscular-dystrophy 2026-01-04T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/67ac5073f98316d3/phase-1-2-trial-demonstrates-safety-and-efficacy-of-autologous-cd133-stem-cell-therapy-for-asherman-syndrome 2026-01-03T22:24:54+00:00 hourly 0.9 https://trial.medpath.com/news/0a46603c0d35cc69/fda-grants-510-k-clearance-to-brainspace-s-intellidrop-automated-brain-fluid-management-system 2026-01-03T20:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/3f626857d916fca7/live-tumor-fragment-platform-enables-real-time-assessment-of-immunotherapy-responses-in-cancer-patients 2026-01-03T18:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/78d1560f37a905b1/genotype-guided-warfarin-dosing-reduces-dose-adjustments-in-asian-patients-across-multiple-subgroups 2026-01-03T12:23:59+00:00 hourly 0.9 https://trial.medpath.com/news/8a168aca89fad666/fda-grants-first-expedited-marketing-authorization-for-altria-s-on-plus-nicotine-pouches 2026-01-03T08:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/73f4ff491b1702ea/sarepta-therapeutics-submits-clinical-trial-application-for-srp-1005-huntington-s-disease-treatment 2026-01-03T03:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/b81b271c38bf4a0c/gh-research-to-update-fda-ind-status-for-novel-mebufotenin-therapy-gh001-in-treatment-resistant-depression 2026-01-03T01:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/f27d11fadf21f27d/dcc-3009-phase-1-2-trial-targets-resistance-mutations-in-advanced-gist-patients 2026-01-02T21:25:50+00:00 hourly 0.9 https://trial.medpath.com/news/cae5778bbc60e081/meta-analysis-reveals-optimal-androgen-deprivation-therapy-duration-for-localized-prostate-cancer-treatment 2026-01-02T21:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/c1dbe80b179a5f61/gabapentin-trial-aims-to-replace-opioids-for-cancer-treatment-related-mucositis-pain 2026-01-02T20:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/81c3e5b5861eaaa2/semaglutide-shows-promise-for-alcohol-use-disorder-treatment-in-emerging-research 2026-01-02T20:24:38+00:00 hourly 0.9 https://trial.medpath.com/news/aa92f530c9593218/mhra-approves-zapomeran-kostaive-first-self-amplifying-mrna-covid-19-vaccine-for-adults 2026-01-02T17:25:30+00:00 hourly 0.9 https://trial.medpath.com/news/3ec625193a831e7c/cdt-equity-partners-with-njs-foresight-bio-advisory-to-accelerate-solid-form-patent-out-licensing 2026-01-02T17:25:28+00:00 hourly 0.9 https://trial.medpath.com/news/9d7e18322d272208/genelux-appoints-dr-jason-litten-as-chief-medical-officer-to-advance-oncolytic-immunotherapy-olvi-vec 2026-01-02T17:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/fef0d0c33ee8c0aa/gubra-expands-facilities-by-70-to-support-growing-peptide-drug-pipeline-and-cro-operations 2026-01-02T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/378ab4f4784b6ce9/tumor-bacteria-burden-emerges-as-key-predictor-of-immunotherapy-resistance-in-head-and-neck-cancer 2026-01-02T12:24:49+00:00 hourly 0.9 https://trial.medpath.com/news/26c1de91a41225f2/pfizer-s-padcev-shows-strong-phase-3-results-in-bladder-cancer-validating-43-billion-seagen-acquisition 2026-01-02T09:24:34+00:00 hourly 0.9 https://trial.medpath.com/news/ee0a9a636c88270a/neovii-pharmaceuticals-appoints-frederic-prince-as-new-ceo-following-christian-loss-s-retirement 2026-01-02T08:24:27+00:00 hourly 0.9 https://trial.medpath.com/news/465480664ae0f818/adalta-secures-exclusive-global-rights-to-novel-car-t-therapy-bzds1901-for-mesothelioma-treatment 2026-01-02T05:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/1684535c55fbeaf9/ai-designed-drug-discovery-reaches-3-billion-milestone-as-isomorphic-labs-partners-with-eli-lilly-and-novartis 2026-01-02T01:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/97f09531704897ee/bayer-launches-phase-4-study-testing-switch-from-tafamidis-to-acoramidis-in-attr-cm-patients 2026-01-02T01:23:54+00:00 hourly 0.9 https://trial.medpath.com/news/636b35cb8af00ca9/tirzepatide-combined-with-hormone-therapy-shows-35-greater-weight-loss-in-postmenopausal-women 2026-01-01T23:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/b3a051957a484633/nhs-patient-achieves-transfusion-independence-following-crispr-gene-therapy-for-beta-thalassaemia 2026-01-01T21:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/545ad04de312c353/delhi-high-court-upholds-helsinn-s-anti-nausea-drug-patent-dismisses-zydus-challenge 2026-01-01T18:24:31+00:00 hourly 0.9 https://trial.medpath.com/news/7e749f58edaa604c/aurobindo-pharma-subsidiary-acquires-khandelwal-labs-non-oncology-portfolio-for-325-crore 2026-01-01T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/81ef81307529484d/xortx-highlights-breakthrough-genetic-research-doubling-known-gout-risk-factors-to-410 2026-01-01T16:25:07+00:00 hourly 0.9 https://trial.medpath.com/news/54dd8a9401e3772a/immunoforge-seeks-global-partners-for-fda-cleared-rare-disease-therapies-at-jpm-2026 2026-01-01T09:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/1a8c75086be27610/bioengineered-viruses-enable-precise-rna-editing-in-macrophages-to-combat-sepsis 2026-01-01T04:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/1a952c0c57de4569/axsome-therapeutics-receives-fda-priority-review-for-axs-05-in-alzheimer-s-disease-agitation 2026-01-01T02:26:08+00:00 hourly 0.9 https://trial.medpath.com/news/720a8b781fbe132f/replimune-stock-surges-131-following-fda-acceptance-of-resubmitted-rp1-application-for-advanced-melanoma 2026-01-01T02:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/8bca7cb051d69796/next-day-hiv-viral-load-testing-fails-to-improve-treatment-uptake-in-clinical-trial 2026-01-01T00:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/0be9f65607388372/intelligent-bio-solutions-secures-strategic-manufacturing-partnership-to-cut-production-costs-by-40 2025-12-31T23:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/54888bc72e7285fd/brazil-modernizes-drug-pricing-framework-with-new-cmed-regulation-effective-april-2026 2025-12-31T22:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/7332c9679894fd60/abbvie-secures-1-1b-deal-for-zelgen-s-dll3-targeting-cancer-therapy 2025-12-31T21:26:54+00:00 hourly 0.9 https://trial.medpath.com/news/03bfe2b8b7f782cb/elanco-receives-usda-approval-for-befrena-anti-il31-monoclonal-antibody-for-canine-dermatitis 2025-12-31T20:24:41+00:00 hourly 0.9 https://trial.medpath.com/news/40cfcbe9baa66e0b/major-pharmaceutical-patent-trials-set-for-2026-include-wegovy-and-covid-19-vaccine-technologies 2025-12-31T17:25:31+00:00 hourly 0.9 https://trial.medpath.com/news/7dbaebaf6ba4d1c7/emmaus-life-sciences-grants-exclusive-north-american-rights-for-sickle-cell-drug-endari-to-neoimmunetech 2025-12-31T17:25:17+00:00 hourly 0.9 https://trial.medpath.com/news/a0784ab3e915ab64/xlife-sciences-partners-twelve-biotech-companies-with-grupo-landsteiner-plans-nasdaq-listing-for-2026 2025-12-31T16:25:53+00:00 hourly 0.9 https://trial.medpath.com/news/04f80ff2fb49c31a/bioatla-secures-40-million-funding-to-advance-ozuriftamab-vedotin-into-phase-3-trial-for-oropharyngeal-cancer 2025-12-31T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/2cb9d73173c55ee2/six-year-evolut-low-risk-data-shows-higher-reintervention-rates-for-tavr-vs-surgery-in-low-risk-aortic-stenosis-patients 2025-12-31T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6fb87786cec3fc1d/male-contraceptive-pill-yct-529-completes-first-human-safety-trial 2025-12-31T13:25:39+00:00 hourly 0.9 https://trial.medpath.com/news/52271db5a48c0a8a/wockhardt-files-european-marketing-application-for-novel-antibiotic-wck-5222-to-combat-drug-resistant-infections 2025-12-31T12:24:43+00:00 hourly 0.9 https://trial.medpath.com/news/6a0e7f254490ff22/co-diagnostics-secures-first-patent-for-point-of-care-pcr-platform-in-australia 2025-12-31T09:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/3e399b460613fd61/real-world-study-shows-inotuzumab-ozogamicin-achieves-57-remission-rate-in-relapsed-refractory-b-all-despite-dose-modifications 2025-12-31T09:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/95b9983060d90588/capsovision-submits-fda-application-for-ai-enhanced-capsule-endoscopy-system 2025-12-31T08:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/ea9eb3aa8eda2dc6/arovella-submits-ind-application-for-first-in-human-trial-of-car-inkt-cell-therapy-ala-101 2025-12-31T05:28:21+00:00 hourly 0.9 https://trial.medpath.com/news/cc1f27f657abc909/maryland-pdab-sets-first-upper-payment-limits-for-diabetes-drugs-as-state-level-price-control-model-gains-momentum 2025-12-31T02:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/5f3d6735682c048b/rhythm-pharmaceuticals-faces-fda-delay-for-setmelanotide-in-hypothalamic-obesity-as-stock-retreats-from-2025-highs 2025-12-31T01:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/617a04a4de5af6ef/two-autophagy-targeting-biotech-companies-advance-neurodegeneration-therapies-to-human-trials 2025-12-31T01:24:52+00:00 hourly 0.9 https://trial.medpath.com/news/eae684c90bda4f42/ultragenyx-completes-bla-submission-for-first-gene-therapy-targeting-glycogen-storage-disease-type-ia 2025-12-31T00:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/7aabec5ee8e44d1e/sinopia-biosciences-secures-nih-grant-to-advance-ai-powered-drug-discovery-platform 2025-12-30T19:25:21+00:00 hourly 0.9 https://trial.medpath.com/news/ff3fb3f6aee9f5e5/neurothera-labs-secures-israeli-patent-for-novel-opioid-pea-combination-to-reduce-side-effects 2025-12-30T18:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/d9ab51be12852e34/imunon-secures-7-million-in-registered-direct-offering-to-advance-phase-3-dna-mediated-immunotherapy 2025-12-30T17:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/d0819f8b1ad53829/weizmann-institute-develops-novel-immunotherapy-strategy-targeting-drug-resistant-cancer-mutations 2025-12-30T17:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/17e7b141eb681e91/inflarx-reports-encouraging-post-hoc-analyses-for-vilobelimab-in-pyoderma-gangrenosum-despite-phase-3-trial-termination 2025-12-30T16:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/4602460baa5ac3cd/uni-bio-science-forms-strategic-alliance-to-advance-growth-factor-combination-therapies-in-regenerative-medicine 2025-12-30T16:24:53+00:00 hourly 0.9 https://trial.medpath.com/news/9159363465b66261/derazantinib-enhances-gemcitabine-efficacy-in-pancreatic-cancer-by-suppressing-nf-kb-and-mapk-pathways 2025-12-30T13:25:13+00:00 hourly 0.9 https://trial.medpath.com/news/2d15b40d224dc79b/henlius-advances-triple-combination-cancer-therapy-with-nmpa-approval-for-hlx43-adc-study 2025-12-30T13:25:03+00:00 hourly 0.9 https://trial.medpath.com/news/ec626e54f9513f06/glp-1-weight-loss-drugs-show-promise-for-addiction-treatment-in-early-clinical-studies 2025-12-30T09:26:06+00:00 hourly 0.9 https://trial.medpath.com/news/63f3b17a6a4567f9/royalty-pharma-acquires-full-evrysdi-royalty-rights-for-240-million-securing-100-interest-in-leading-sma-treatment 2025-12-30T06:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/cdf8563fcb48a7a0/federal-court-blocks-hhs-340b-drug-rebate-pilot-program-protecting-hospital-discount-system 2025-12-30T03:47:10+00:00 hourly 0.9 https://trial.medpath.com/news/0d3297b9cb6acded/subgroup-analysis-of-phase-3-focus-study-reveals-optimal-patient-selection-for-melphalan-hepatic-delivery-system-in-uveal-melanoma 2025-12-30T03:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/7cd23dbdfb6dc51a/verastem-discontinues-kras-g12c-trial-to-focus-on-promising-g12d-inhibitor-with-69-response-rate 2025-12-30T03:26:45+00:00 hourly 0.9 https://trial.medpath.com/news/4133f18b55e821de/traditional-chinese-herbal-formula-shows-superior-kidney-function-preservation-in-diabetic-kidney-disease-trial 2025-12-29T23:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/0393468c20956697/bluejay-diagnostics-completes-commercial-scale-il-6-antibody-production-for-sepsis-diagnostic-platform 2025-12-29T23:28:36+00:00 hourly 0.9 https://trial.medpath.com/news/c4e4ad5aaff09213/imunon-reports-strong-phase-3-ovation-3-enrollment-progress-as-imnn-001-shows-promise-in-advanced-ovarian-cancer-treatment 2025-12-29T23:27:37+00:00 hourly 0.9 https://trial.medpath.com/news/01279163276cec76/work-medical-receives-regulatory-approval-for-ai-powered-blood-cell-morphology-analyzer 2025-12-29T23:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/b075a63f0d5df2d4/oncodesign-precision-medicine-and-navigo-proteins-terminate-radiotheranostics-collaboration 2025-12-29T23:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/13451d7068ddf7ba/ohsu-researchers-discover-breast-cancer-drug-palbociclib-overcomes-venetoclax-resistance-in-acute-myeloid-leukemia 2025-12-29T22:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/02031c416db3493d/ultragenyx-s-setrusumab-fails-two-phase-3-trials-for-rare-bone-disease-shares-plummet-43 2025-12-29T22:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/31951da69bbbbd95/conavi-medical-submits-next-generation-hybrid-imaging-system-to-fda-as-clinical-guidelines-support-intravascular-imaging 2025-12-29T19:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/289ef9fcd382b63c/lupin-secures-exclusive-rights-to-novel-fortnightly-glp-1-receptor-agonist-bofanglutide-for-indian-market 2025-12-29T19:41:23+00:00 hourly 0.9 https://trial.medpath.com/news/6e188a7c654c856b/cbih-pursues-patent-for-cannabinoid-based-therapy-targeting-opioid-addiction-recovery 2025-12-29T19:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/a4df6e33f48e9d38/lund-university-researchers-identify-statin-phenothiazine-combination-as-potential-neuroblastoma-treatment-using-machine-learning 2025-12-29T19:40:47+00:00 hourly 0.9 https://trial.medpath.com/news/c0122e4fb6a38897/china-approves-neffy-as-first-community-use-epinephrine-product-for-severe-allergic-reactions 2025-12-29T19:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/7429e00d273e6e16/azenta-divests-b-medical-systems-for-63-million-to-focus-on-core-life-sciences-portfolio 2025-12-29T19:34:30+00:00 hourly 0.9 https://trial.medpath.com/news/5b2f9ad8b71e2849/setrusumab-phase-3-trials-in-osteogenesis-imperfecta-show-mixed-results-across-age-groups 2025-12-29T19:33:46+00:00 hourly 0.9 https://trial.medpath.com/news/409a4297ad24716e/unicycive-therapeutics-resubmits-nda-for-novel-phosphate-binder-targeting-hyperphosphatemia-in-dialysis-patients 2025-12-29T19:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/3e2eceecef3abac8/genmab-discontinues-acasunlimab-development-to-focus-on-late-stage-pipeline-programs 2025-12-29T19:32:56+00:00 hourly 0.9 https://trial.medpath.com/news/a48dcc76f94a680d/theriva-biologics-receives-ema-scientific-advice-for-vcn-01-phase-3-trial-in-metastatic-pancreatic-cancer 2025-12-29T19:32:00+00:00 hourly 0.9 https://trial.medpath.com/news/7a7ab87ccb0f1405/cel-sci-advances-multikine-toward-registration-with-212-patient-confirmatory-study-for-head-and-neck-cancer 2025-12-29T19:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/a4a899e104d3be47/zevra-therapeutics-expands-global-access-to-miplyffa-through-distribution-partnership-with-uniphar 2025-12-29T19:30:34+00:00 hourly 0.9 https://trial.medpath.com/news/c0554a43ca0d3d75/tonix-pharmaceuticals-advances-tnx-4800-monoclonal-antibody-for-lyme-disease-prevention-with-fda-meeting-planned-for-2026 2025-12-29T19:30:20+00:00 hourly 0.9 https://trial.medpath.com/news/af59e7e7fc65eb6e/tonix-pharmaceuticals-secures-20-million-funding-to-advance-fibromyalgia-treatment-and-pipeline-development 2025-12-29T19:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/b4f58e997b75e8f1/gensight-biologics-secures-eur2-9-million-in-latest-fundraising-round-for-gene-therapy-development 2025-12-29T18:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/da0f77a901705e98/aspen-pharmacare-divests-1-6-billion-apac-operations-to-focus-on-glp-1-drug-production 2025-12-29T18:27:01+00:00 hourly 0.9 https://trial.medpath.com/news/e10c68d6705ef8af/adlai-nortye-partners-with-ask-pharm-in-230-million-deal-for-pan-ras-inhibitor-an9025-in-greater-china 2025-12-29T18:26:18+00:00 hourly 0.9 https://trial.medpath.com/news/fe9fbd23cad927f0/transcenta-therapeutics-partners-with-eirgenix-to-license-continuous-biomanufacturing-platform-for-affordable-biologics 2025-12-29T18:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/bfafb99c61ed2c11/intas-pharmaceuticals-partners-with-integrimedical-to-launch-india-s-first-needle-free-ivf-injection-system 2025-12-29T15:26:05+00:00 hourly 0.9 https://trial.medpath.com/news/7584ebd36a0777cc/corteva-and-hexagon-bio-launch-multi-million-dollar-joint-venture-for-nature-inspired-agricultural-and-pharmaceutical-solutions 2025-12-29T14:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/de3d7009ca0550e9/smart-nanoparticles-enable-disease-responsive-gene-therapy-for-osteoarthritis 2025-12-29T13:24:45+00:00 hourly 0.9 https://trial.medpath.com/news/4391e0679f30d0fa/fosun-pharmaceutical-faces-market-skepticism-over-200-million-green-valley-acquisition-amid-regulatory-concerns 2025-12-29T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/55b9556ac152cd88/who-prequalifies-first-covid-19-rapid-antigen-tests-for-long-term-global-use 2025-12-29T01:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/2eb53ebadf0beba8/catnon-trial-final-results-confirm-adjuvant-temozolomide-benefit-in-idh-mutant-anaplastic-glioma 2025-12-29T01:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/05bcb23342901e90/next-generation-mrna-vaccines-demonstrate-protective-effects-against-multidrug-resistant-enterobacteriaceae 2025-12-28T01:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/dcbdcffb3e78249f/fda-grants-breakthrough-therapy-designation-to-oculis-privosegtor-for-optic-neuritis-treatment 2025-12-28T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/616e8888528233ec/johnson-johnson-halts-mid-stage-eczema-drug-trial-after-failing-to-meet-efficacy-targets 2025-12-27T21:32:45+00:00 hourly 0.9 https://trial.medpath.com/news/7edd92dbe02b7ab4/fda-approves-first-at-home-brain-stimulation-device-for-depression-treatment 2025-12-27T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/091fbeee5d72a7c0/irlab-advances-first-in-class-apathy-treatment-irl757-into-phase-ib-trial-for-parkinson-s-disease 2025-12-27T13:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/2e2f9b426873169e/metformin-enters-largest-ever-clinical-trial-for-abdominal-aortic-aneurysm-treatment 2025-12-27T05:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/24a6c3501aeb4c68/biohaven-s-major-depressive-disorder-drug-fails-phase-2-trial-primary-endpoint 2025-12-26T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/4cd51fa52714752b/novel-plga-nanoparticle-system-enhances-cisplatin-silibinin-combination-for-cervical-cancer-treatment 2025-12-26T21:29:51+00:00 hourly 0.9 https://trial.medpath.com/news/f8118bb3b6f4f8a0/fda-clears-wave-of-spine-and-orthopedic-robotics-systems-in-2025 2025-12-26T21:28:57+00:00 hourly 0.9 https://trial.medpath.com/news/a46cb387eef3480f/novel-her2-targeting-nanoagent-enables-precise-antibody-delivery-for-cancer-treatment 2025-12-26T17:29:33+00:00 hourly 0.9 https://trial.medpath.com/news/6c0c1c1663a774f4/johnson-johnson-discontinues-mid-stage-eczema-trial-after-jnj-5939-fails-to-meet-efficacy-goals 2025-12-26T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/2b777d1d5903e970/johnson-johnson-terminates-phase-2b-duplex-ad-study-of-jnj-95475939-following-interim-efficacy-analysis 2025-12-26T17:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/5f39ffcbe76c5a6e/can-fite-secures-brazilian-patent-for-a3-adenosine-receptor-agonists-in-sexual-dysfunction-treatment 2025-12-26T13:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/d298cacdc638545a/biofabri-and-bharat-biotech-advance-technology-transfer-for-mtbvac-tuberculosis-vaccine-to-expand-global-access 2025-12-26T13:31:08+00:00 hourly 0.9 https://trial.medpath.com/news/d982260d5669f8a9/strides-pharma-us-facility-receives-four-fda-observations-following-routine-inspection 2025-12-26T13:30:35+00:00 hourly 0.9 https://trial.medpath.com/news/f0eabc3170961e97/abl-bio-secures-55-million-from-eli-lilly-for-grabody-bispecific-antibody-platform-development 2025-12-26T09:40:24+00:00 hourly 0.9 https://trial.medpath.com/news/8ef14c655c3f11f9/sk-chemicals-partners-with-nextgen-bioscience-to-advance-ai-driven-drug-discovery-platform 2025-12-26T09:39:08+00:00 hourly 0.9 https://trial.medpath.com/news/dab07a8c61646d14/sun-pharma-s-taro-unit-recalls-17664-units-of-ciclopirox-shampoo-in-us-due-to-manufacturing-quality-issues 2025-12-26T09:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/8fd26d945a29b23b/henlius-advances-hlx22-phase-3-trial-for-her2-positive-gastric-cancer-at-asco-gi-2026 2025-12-26T09:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/d45e3c3ff02c9236/novo-nordisk-launches-phase-3-trial-testing-ziltivekimab-for-coronary-plaque-reduction-after-heart-attack 2025-12-26T09:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/ab10b0ab7f0cbeba/tyra-biosciences-gains-s-p-biotechnology-index-inclusion-as-fgfr3-focused-pipeline-advances 2025-12-26T09:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/e34b0593c0a20341/major-study-questions-tramadol-s-efficacy-for-chronic-pain-reveals-cardiovascular-risks 2025-12-26T09:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/d535c5697be53c4c/china-approves-world-s-first-ctla-4-antibody-for-neoadjuvant-colon-cancer-treatment 2025-12-26T09:20:49+00:00 hourly 0.9 https://trial.medpath.com/news/27e327d54591f895/modalis-publishes-breakthrough-crispr-gene-activation-study-for-rare-muscular-dystrophy-treatment 2025-12-26T09:20:37+00:00 hourly 0.9 https://trial.medpath.com/news/af81db2910b47272/new-study-reveals-adhd-stimulants-work-through-brain-s-reward-and-alertness-centers-not-attention-networks 2025-12-26T09:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/2f1786c66440a0a2/edgewise-therapeutics-reports-positive-phase-2-data-for-cardiac-sarcomere-modulator-edg-7500-in-hypertrophic-cardiomyopathy 2025-12-26T09:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/684a1df7b934b46b/lexaria-s-dehydratech-semaglutide-shows-48-reduction-in-side-effects-compared-to-rybelsus-in-phase-1b-trial 2025-12-25T05:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/a36d511f86e82b95/abbvie-advances-two-clinical-trials-icalcaprant-for-depression-and-abbv-444-for-dry-eye-disease 2025-12-25T05:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/be334ce5d3b1ca8a/caliway-submits-ind-for-phase-2-study-of-cbl-514-combined-with-zepbound-for-weight-management 2025-12-25T05:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/b37edfa18115adad/arrowhead-pharmaceuticals-reports-strong-q1-2026-results-with-redemplo-launch-success-and-promising-obesity-pipeline-data 2025-12-25T03:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/4e250519da5814f6/liquidia-loses-bid-to-dismiss-united-therapeutics-patent-lawsuit-over-yutrepia-lung-drug 2025-12-25T01:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/f15834a4a54a3e1a/microport-medbot-receives-nmpa-approval-for-unipath-bronchoscopic-surgical-robot-becomes-first-company-to-commercialize-full-spectrum-of-robotic-surgery-systems 2025-12-25T01:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/0edc06463ede909c/adama-and-basf-partner-to-commercialize-novel-fungicide-gilboa-for-european-cereal-disease-management 2025-12-25T01:29:29+00:00 hourly 0.9 https://trial.medpath.com/news/d0a382070b5d3562/euda-health-launches-comprehensive-stem-cell-platform-in-china-with-national-clinical-network 2025-12-24T21:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/b71a3f2f30962432/omeros-receives-fda-approval-for-first-in-class-ta-tma-therapy-yartemlea 2025-12-24T21:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/3338ac9142e56d69/immucell-pivots-strategy-after-fda-setback-expands-first-defense-r-sales-force-by-50 2025-12-24T21:33:55+00:00 hourly 0.9 https://trial.medpath.com/news/5fa7ddf65217c2d1/modified-measles-virus-shows-promise-as-novel-mesothelioma-treatment-in-preclinical-studies 2025-12-24T21:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/f5c3f1d641bfb2d8/traditional-chinese-medicine-zishen-yutai-pill-demonstrates-significant-improvement-in-live-birth-rates-for-women-of-advanced-maternal-age 2025-12-24T21:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/69e6246e59b7b635/biohaven-s-bhv-7000-fails-to-meet-primary-endpoint-in-phase-2-major-depression-trial 2025-12-24T21:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/672ae73308120a9c/fda-approves-yartemlea-as-first-therapy-for-life-threatening-transplant-complication-ta-tma 2025-12-24T17:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/8923057ac3694967/kp-2-covid-19-vaccines-demonstrate-sustained-70-effectiveness-over-12-months-in-major-us-study 2025-12-24T17:30:55+00:00 hourly 0.9 https://trial.medpath.com/news/1d1c529d5a7860f8/hksh-medical-group-partners-with-chinese-academy-cancer-hospital-to-expand-proton-therapy-access-in-greater-bay-area 2025-12-24T17:30:42+00:00 hourly 0.9 https://trial.medpath.com/news/d1d22ae01053a092/fda-approves-first-ever-ta-tma-therapy-narsoplimab-shows-61-response-rate-in-high-risk-patients 2025-12-24T17:28:08+00:00 hourly 0.9 https://trial.medpath.com/news/fb486ec350795ea6/mabwell-s-anti-st2-antibody-9mw1911-receives-fda-ind-clearance-for-copd-phase-iia-trial 2025-12-24T17:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/5e65311423102b00/singlera-genomics-partners-with-pure-medical-to-expand-dna-methylation-cancer-detection-technology-across-europe 2025-12-24T13:31:41+00:00 hourly 0.9 https://trial.medpath.com/news/6e71d6570e0add49/italfarmaco-and-jcr-pharmaceuticals-form-strategic-partnership-to-commercialize-givinostat-for-duchenne-muscular-dystrophy-in-japan 2025-12-24T13:29:47+00:00 hourly 0.9 https://trial.medpath.com/news/efca3bfe756b2eb4/nice-approves-bevacizumab-for-metastatic-colorectal-cancer-following-biosimilar-availability 2025-12-24T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/779710d05c733c0d/agenus-reports-promising-results-for-botensilimab-balstilimab-combination-in-treatment-refractory-ovarian-cancer 2025-12-24T05:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/0c21ae56f2fbcd6e/fda-clears-first-extended-depth-of-focus-contact-lens-for-presbyopia-treatment 2025-12-24T05:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/06fea19da7986ff3/trump-administration-drives-pharmaceutical-manufacturing-reshoring-initiative-as-industry-faces-supply-chain-vulnerabilities 2025-12-24T03:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/d904221610a05d5a/panitumumab-emerges-as-viable-alternative-to-cetuximab-in-braf-mutated-colorectal-cancer-treatment 2025-12-24T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/0565fc21e92ff0b5/structure-therapeutics-oral-obesity-drug-gsbr-1290-advances-through-phase-2-trials-amid-valuation-concerns 2025-12-24T01:32:25+00:00 hourly 0.9 https://trial.medpath.com/news/22577d4ee3e9c1dc/health-canada-approves-tevimbra-for-rare-throat-cancer-marking-first-immunotherapy-option-for-nasopharyngeal-carcinoma 2025-12-24T01:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/203b1350d238f6f3/sn-bioscience-secures-fda-orphan-drug-designation-for-nanoparticle-cancer-drug-snb-101-in-gastric-cancer 2025-12-24T01:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/65213cb1037ed7b6/janux-therapeutics-appoints-william-go-as-chief-medical-officer-to-lead-clinical-development 2025-12-24T01:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/1203a5c07a2a4680/researchers-achieve-complete-alzheimer-s-reversal-in-mouse-models-through-nad-restoration 2025-12-24T01:30:40+00:00 hourly 0.9 https://trial.medpath.com/news/6a1bfb4184e4af27/vaccinex-secures-60-million-to-advance-phase-2b-trial-of-alzheimer-s-drug-pepinemab 2025-12-23T21:32:46+00:00 hourly 0.9 https://trial.medpath.com/news/905c8792a69e3b83/semaglutide-shows-direct-cartilage-protective-effects-in-osteoarthritis-beyond-weight-loss 2025-12-23T21:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/46022faa55e14ab3/fda-approves-edwards-sapien-m3-as-first-transseptal-mitral-valve-replacement-system 2025-12-23T21:29:04+00:00 hourly 0.9 https://trial.medpath.com/news/f15ca61b5b52f3bc/monoclonal-antibody-nebokitug-shows-promise-for-rare-liver-disease-primary-sclerosing-cholangitis 2025-12-23T21:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/7f5c0f0b98de7b5d/lixte-biotechnology-doubles-enrollment-in-ovarian-clear-cell-cancer-trial-combining-lb-100-with-gsk-s-dostarlimab 2025-12-23T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/67411883c5ca5965/trinity-biotech-secures-5-million-funding-and-restructures-debt-to-advance-continuous-glucose-monitoring-technology 2025-12-23T17:41:07+00:00 hourly 0.9 https://trial.medpath.com/news/f0100406ce6bbd17/biocon-biologics-secures-full-global-manufacturing-rights-for-adalimumab-biosimilar-hulio 2025-12-23T17:32:49+00:00 hourly 0.9 https://trial.medpath.com/news/c53b8130e1a9fcb9/nature-cell-advances-vascostem-cli-development-with-nobel-laureate-advisory-support 2025-12-23T17:31:58+00:00 hourly 0.9 https://trial.medpath.com/news/45dab87b9a6f9eac/windtree-therapeutics-divests-cardiovascular-pipeline-to-seismic-pharmaceutical-holdings-in-strategic-asset-sale 2025-12-23T17:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/6f38dfd63544e7e2/china-approves-cobenfy-first-novel-schizophrenia-therapy-in-over-70-years 2025-12-23T17:31:21+00:00 hourly 0.9 https://trial.medpath.com/news/3a4d581d945b314d/asahi-kasei-pharma-expands-autoimmune-disease-pipeline-through-strategic-license-deal-and-r-d-hub-relocation 2025-12-23T17:30:49+00:00 hourly 0.9 https://trial.medpath.com/news/1623b6ba30cab465/fda-recommends-second-phase-3-trial-for-reviva-s-brilaroxazine-in-schizophrenia-treatment 2025-12-23T17:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/8508b1a2e6d0b628/dinaqor-unveils-breakthrough-catheter-based-platform-for-precision-gene-therapy-delivery 2025-12-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/3292f7f17c808eb7/coya-therapeutics-receives-health-canada-approval-to-expand-als-trial-to-canadian-sites 2025-12-23T17:26:59+00:00 hourly 0.9 https://trial.medpath.com/news/503075b512137009/brainsway-secures-major-insurance-coverage-expansions-for-deep-tms-therapy-in-adolescent-depression 2025-12-23T17:07:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f1abcd2d608a431/leads-biolabs-and-dianthus-therapeutics-initiate-phase-1-trial-of-novel-bifunctional-autoimmune-therapy-lbl-047 2025-12-23T13:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/a62baf4f7615ad2a/kashiv-biosciences-secures-77-million-financing-to-build-india-s-largest-single-use-biologics-manufacturing-facility 2025-12-23T13:34:06+00:00 hourly 0.9 https://trial.medpath.com/news/1896c64293bea3e0/initiator-pharma-begins-patient-enrollment-for-first-vulvodynia-treatment-study 2025-12-23T13:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/416c245241cff35f/biomerica-s-infoods-ibs-test-shows-59-response-rate-in-real-world-study-secures-300-medicare-payment 2025-12-23T13:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/42f836053c9519cd/japan-approves-dupixent-for-pediatric-asthma-in-children-aged-6-11-years 2025-12-23T09:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/ca8d7774efb1f58a/fujifilm-completes-japan-s-largest-bio-cdmo-facility-with-world-class-bioreactor-capacity 2025-12-23T05:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/cb5f703441593df8/fda-issues-final-guidance-on-bioresearch-monitoring-inspection-practices-to-enhance-clinical-trial-oversight 2025-12-23T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/4705affffda65db1/hope-biosciences-stem-cell-therapy-shows-significant-motor-function-improvements-in-phase-ii-parkinson-s-disease-trial 2025-12-23T05:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/76cfa0fa03412cfb/medipost-secures-140-million-funding-and-japan-partnership-to-advance-stem-cell-therapy-for-knee-osteoarthritis 2025-12-23T03:27:36+00:00 hourly 0.9 https://trial.medpath.com/news/b6b31ccd37ef2a42/ab-science-secures-us-patent-for-masitinib-in-sickle-cell-disease-treatment-through-2040 2025-12-23T01:36:30+00:00 hourly 0.9 https://trial.medpath.com/news/324450045416166a/eurofins-lancaster-laboratories-announces-147-million-expansion-creating-250-jobs-in-pennsylvania 2025-12-23T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/0831ac8318cf31bc/shield-therapeutics-secures-fda-approval-extension-for-accrufer-in-pediatric-patients-eyes-china-market-entry-in-q1-2026 2025-12-23T01:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/c51af9d7be069b11/community-advisors-dramatically-improve-asthma-clinical-trial-outcomes-through-protocol-modifications 2025-12-23T01:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/e7293dfee062387f/neurocrine-s-phase-3-valbenazine-trial-for-dyskinetic-cerebral-palsy-fails-to-meet-primary-endpoints 2025-12-23T01:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/b34ae95e7064b0f0/puma-biotechnology-joins-nasdaq-biotechnology-index-following-commercial-success-and-clinical-progress 2025-12-23T01:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/199f274e9e68f451/fda-expands-ferric-maltol-approval-to-adolescents-for-iron-deficiency-treatment 2025-12-23T01:28:04+00:00 hourly 0.9 https://trial.medpath.com/news/5edc671d8dd21ad3/samsung-biologics-acquires-first-u-s-manufacturing-facility-for-280m-in-maryland 2025-12-22T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/03a56f1eedc1fd2a/trabectedin-olaparib-combination-shows-promise-for-advanced-soft-tissue-sarcoma-subgroups 2025-12-22T21:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/35c241196bf0065f/qalsody-shows-unprecedented-functional-recovery-in-sod1-als-patients-over-3-5-years-jama-neurology-study-reports 2025-12-22T21:33:51+00:00 hourly 0.9 https://trial.medpath.com/news/97ce4be43d9cf3ed/johns-hopkins-develops-precision-antibody-drug-conjugate-for-trbc2-positive-t-cell-cancers 2025-12-22T21:33:45+00:00 hourly 0.9 https://trial.medpath.com/news/2b2c8e1d52cf205b/niagen-bioscience-acquires-core-nad-patent-portfolio-from-queen-s-university-belfast 2025-12-22T21:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/26c951d40b2a4ddb/prolific-risk-score-becomes-first-ipf-biomarker-accepted-into-fda-qualification-program 2025-12-22T21:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/5a858b0626f912f9/fda-grants-full-approval-for-pimobendan-to-delay-congestive-heart-failure-in-dogs 2025-12-22T21:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/32b7758a5929d349/tofersen-shows-long-term-efficacy-in-rare-genetic-als-stabilizing-disease-and-improving-function-in-quarter-of-patients 2025-12-22T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/a68846ebf4f20af3/oryzon-secures-japanese-patent-for-iadademstat-combination-therapy-in-cancer-treatment 2025-12-22T17:39:41+00:00 hourly 0.9 https://trial.medpath.com/news/e9a5b5cd6a182475/crispr-therapeutics-reports-promising-results-for-zugo-cel-car-t-therapy-in-autoimmune-diseases-and-blood-cancers 2025-12-22T17:36:42+00:00 hourly 0.9 https://trial.medpath.com/news/6d67097699badd9d/quantum-x-labs-files-patent-for-quantum-enhanced-clinical-trial-technology 2025-12-22T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/8f32851cbb3767b3/immutep-s-first-in-class-lag-3-agonist-shows-promising-immunosuppressive-effects-in-phase-i-autoimmune-disease-trial 2025-12-22T17:36:08+00:00 hourly 0.9 https://trial.medpath.com/news/fc6650167e971bd9/atea-pharmaceuticals-completes-enrollment-in-phase-3-hepatitis-c-trial-with-novel-drug-combination 2025-12-22T17:36:01+00:00 hourly 0.9 https://trial.medpath.com/news/44ff350f55d10a7f/aqualung-therapeutics-receives-fda-clearance-for-phase-2a-progressive-pulmonary-fibrosis-trial 2025-12-22T17:34:56+00:00 hourly 0.9 https://trial.medpath.com/news/9614a8a501f10398/beyond-celiac-investments-funds-rheumagen-s-hla-gene-editing-platform-for-celiac-disease-treatment 2025-12-22T17:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/4dbd11ada2726df5/ema-identifies-38-cases-of-t-cell-malignancies-following-car-t-cell-therapy 2025-12-22T17:34:29+00:00 hourly 0.9 https://trial.medpath.com/news/d74796c229896f7c/summit-therapeutics-submits-bla-for-ivonescimab-in-egfr-mutated-nsclc-as-analysts-spotlight-phase-iii-pipeline 2025-12-22T17:33:42+00:00 hourly 0.9 https://trial.medpath.com/news/e793beb80bc20420/r-pharm-advances-three-cancer-drugs-through-clinical-development-including-novel-antiandrogen-for-prostate-cancer 2025-12-22T17:33:27+00:00 hourly 0.9 https://trial.medpath.com/news/031eb10f801315cf/huonslab-submits-biologics-license-application-for-recombinant-human-hyaluronidase-hydizymetm 2025-12-22T17:33:24+00:00 hourly 0.9 https://trial.medpath.com/news/fcd925730af2ecdc/arrivent-initiates-pivotal-phase-3-alpacca-trial-for-firmonertinib-in-egfr-pacc-mutant-nsclc 2025-12-22T17:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/7aefb39248a03110/pt-112-demonstrates-promising-efficacy-in-recurrent-thymoma-phase-2-trial 2025-12-22T17:31:35+00:00 hourly 0.9 https://trial.medpath.com/news/96385cc009e7f593/transcode-therapeutics-appoints-jack-e-stover-to-board-of-directors-to-strengthen-rna-and-immuno-oncology-leadership 2025-12-22T17:31:20+00:00 hourly 0.9 https://trial.medpath.com/news/f5b2f82dea66a2ab/landmark-nature-study-reveals-alzheimer-s-disease-prevalence-soars-to-65-in-adults-over-90 2025-12-22T17:30:05+00:00 hourly 0.9 https://trial.medpath.com/news/4b594ea3482fcb5f/fda-expands-dermatology-drug-labels-in-2025-with-five-new-indications-across-multiple-skin-conditions 2025-12-22T17:29:34+00:00 hourly 0.9 https://trial.medpath.com/news/3212edd3a99bae9a/flagship-pioneering-and-repertoire-immune-medicines-partner-with-pfizer-to-develop-tcr-bispecifics-for-metastatic-prostate-cancer 2025-12-22T17:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/61c75a59e7c94374/uk-clinical-trials-activity-surges-9-as-ps50m-research-centre-and-regulatory-reforms-drive-innovation 2025-12-22T17:28:50+00:00 hourly 0.9 https://trial.medpath.com/news/5914729054a28145/fda-finalizes-guidance-on-clinical-trial-participation-mandating-broader-eligibility-and-real-world-population-representation 2025-12-22T17:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/0d27f5cdccc22d96/fda-issues-complete-response-letter-for-corcept-s-relacorilant-in-hypercortisolism-treatment 2025-12-22T15:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/5148f2e7f835722c/faron-launches-blaze-trial-with-icr-to-test-novel-approach-for-overcoming-immunotherapy-resistance 2025-12-22T13:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc2c7fea4b0461a4/korean-pharmaceutical-industry-faces-3-6-trillion-won-annual-loss-from-government-s-generic-drug-price-cut-plan 2025-12-22T13:38:19+00:00 hourly 0.9 https://trial.medpath.com/news/8167891d09c1577a/guardant-health-japan-secures-first-esr1-mutation-liquid-biopsy-approval-for-breast-cancer-treatment-selection 2025-12-22T13:38:16+00:00 hourly 0.9 https://trial.medpath.com/news/5d66144d4177190c/iit-madras-and-australian-researchers-develop-precision-nanoinjection-platform-for-targeted-breast-cancer-treatment 2025-12-22T13:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/aebc6144f5a4fe7c/chugai-secures-japanese-approval-for-tecentriq-in-rare-thymic-carcinoma 2025-12-22T13:34:32+00:00 hourly 0.9 https://trial.medpath.com/news/63086941d884199e/bayer-s-finerenone-gains-regulatory-momentum-for-heart-failure-treatment-across-global-markets 2025-12-22T13:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/119f7cad3409e21f/japan-approves-zynyz-for-first-line-treatment-of-advanced-anal-cancer 2025-12-22T13:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/affa11dd32384ff0/astrazeneca-s-ceralasertib-imfinzi-combination-fails-phase-3-lung-cancer-trial-while-enhertu-gains-fda-breakthrough-designation 2025-12-22T13:32:08+00:00 hourly 0.9 https://trial.medpath.com/news/87a13b17b5272220/shionogi-acquires-radicava-business-from-tanabe-pharma-for-2-5-billion-to-strengthen-rare-disease-portfolio 2025-12-22T13:31:50+00:00 hourly 0.9 https://trial.medpath.com/news/1917d57bb887c651/zambon-biotech-initiates-phase-3b-trial-for-novel-parkinson-s-disease-treatment-ipx203 2025-12-22T13:31:38+00:00 hourly 0.9 https://trial.medpath.com/news/ed1339b1d67b9e68/blood-test-identifies-prostate-cancer-patients-unlikely-to-benefit-from-cabazitaxel-chemotherapy 2025-12-22T13:31:24+00:00 hourly 0.9 https://trial.medpath.com/news/2175faa08ecb44e9/mondego-bio-advances-ai-designed-ptpn2-inhibitor-ze00-0388-to-phase-1-clinical-trials 2025-12-22T13:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/fc0ba6c85797bfda/astrazeneca-s-latify-phase-iii-trial-of-ceralasertib-plus-imfinzi-fails-to-meet-primary-endpoint-in-advanced-lung-cancer 2025-12-22T09:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/ca8ddced583edccc/abl-bio-and-neok-bio-advance-first-in-class-bispecific-adc-abl206-to-phase-1-clinical-trial 2025-12-22T09:31:44+00:00 hourly 0.9 https://trial.medpath.com/news/339eae0245e0de67/hong-kong-launches-one-on-one-pre-application-meetings-to-accelerate-drug-approvals-under-1-mechanism 2025-12-22T09:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/279c85a51e395306/ipsen-secures-global-rights-to-novel-lrrc15-targeting-adc-in-1-06-billion-deal-with-simcere-zaiming 2025-12-22T09:30:01+00:00 hourly 0.9 https://trial.medpath.com/news/fb9e9d3064a45a4c/ipsen-expands-oncology-partnership-with-universite-de-montreal-and-iricor-adding-two-map-kinase-related-discovery-programs 2025-12-22T09:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/76cf8dee58ebeffb/telix-pharmaceuticals-advances-china-phase-3-trial-for-illuccix-while-addressing-fda-regulatory-challenges 2025-12-22T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/5ece3aa41db70757/polyrizon-submits-fda-pre-request-for-pl-16-viral-blocker-with-over-90-efficacy-against-respiratory-viruses 2025-12-22T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/b1621387d72d3ca3/granules-pharmaceuticals-receives-tentative-fda-approval-for-generic-adhd-treatment 2025-12-22T09:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/ba88caedeee5a48f/entera-bio-reports-breakthrough-in-oral-pth-therapy-for-hypoparathyroidism-with-once-daily-tablet 2025-12-22T08:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/3682304165f19665/pluri-expands-manufacturing-partnership-with-remedy-cell-achieves-clinical-grade-production-for-fibrotic-disease-therapy 2025-12-22T06:59:00+00:00 hourly 0.9 https://trial.medpath.com/news/4ff090324ef5657a/windward-bio-secures-700m-licensing-deal-for-dual-target-bispecific-antibody-win027 2025-12-22T05:29:35+00:00 hourly 0.9 https://trial.medpath.com/news/b027925aaf86bc77/us-fda-updates-safety-reporting-guidelines-for-bioavailability-and-bioequivalence-studies-indian-pharma-industry-responds-positively 2025-12-22T05:28:41+00:00 hourly 0.9 https://trial.medpath.com/news/e1df96473594df79/blood-test-predicts-crohn-s-disease-years-before-symptoms-emerge-opening-door-to-prevention 2025-12-22T05:28:38+00:00 hourly 0.9 https://trial.medpath.com/news/ff1299abe23f0863/recursion-pharmaceuticals-ai-discovered-drug-rec-4881-shows-promise-in-phase-1b-2-fap-trial 2025-12-22T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/05737a720b463f8d/samyang-biopharmaceuticals-advances-mrna-therapy-for-idiopathic-pulmonary-fibrosis-using-sens-gene-delivery-platform 2025-12-22T05:28:27+00:00 hourly 0.9 https://trial.medpath.com/news/64ab9e72953912f5/content-not-suitable-for-medical-publication 2025-12-22T05:28:03+00:00 hourly 0.9 https://trial.medpath.com/news/071bacd5e695a4fd/memphasys-secures-eur525000-european-supply-deal-for-felix-sperm-isolation-technology 2025-12-22T05:28:00+00:00 hourly 0.9 https://trial.medpath.com/news/01843d0670660702/hong-kong-establishes-real-world-study-center-to-accelerate-drug-development-in-greater-bay-area 2025-12-22T05:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/5aad35b776984fc8/neuren-pharmaceuticals-advances-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome-with-promising-phase-2-results 2025-12-22T05:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/6e6337d03c0a8f9a/telix-pharmaceuticals-achieves-positive-phase-3-results-for-prostate-cancer-imaging-agent-in-china 2025-12-22T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/93baaefe365b95ca/scienture-secures-patent-protection-for-rezenopy-highest-strength-naloxone-nasal-spray-ahead-of-q2-2026-launch 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b4bdb9d202f14bb/wasatch-biolabs-partners-with-agilent-to-advance-native-read-targeted-sequencing-technology 2025-12-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1ffc98f004eda3b5/uk-launches-expanded-type-1-diabetes-screening-program-as-genetic-risk-tools-show-promise-for-early-detection 2025-12-21T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/9ddd0ac14b68cb06/rna-drug-pioneer-ribobio-passes-hong-kong-ipo-hearing-with-2b-partnership-portfolio 2025-12-21T21:31:48+00:00 hourly 0.9 https://trial.medpath.com/news/e713eee754825037/zasocitinib-shows-phase-3-superiority-over-apremilast-in-dermatology-trials 2025-12-21T21:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/66b8cb592d9c6820/biohaven-s-bhv-1510-shows-promising-early-cancer-data-in-combination-trial 2025-12-21T17:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/33b365f712c69a26/arcturus-therapeutics-faces-59-stock-decline-following-mixed-cystic-fibrosis-trial-results 2025-12-21T17:32:24+00:00 hourly 0.9 https://trial.medpath.com/news/d2b417180386b2b8/antisense-oligonucleotide-therapy-reverses-developmental-defects-in-spinal-muscular-atrophy-organoids 2025-12-21T17:29:50+00:00 hourly 0.9 https://trial.medpath.com/news/faf00d2f22a69101/t-maximum-s-allogeneic-car-t-therapy-mt027-receives-fda-clearance-for-phase-ii-glioblastoma-trial 2025-12-21T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/0b0883cd0e37ca56/jacobio-pharma-partners-with-astrazeneca-in-2-billion-pan-kras-inhibitor-deal 2025-12-21T17:28:09+00:00 hourly 0.9 https://trial.medpath.com/news/fac7c104cfad9921/fda-approves-turkish-scientist-s-lung-cancer-drug-for-clinical-trials-after-six-years-of-research 2025-12-21T17:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/bdcc48a3428054eb/mit-develops-needle-free-glucose-monitor-using-light-based-technology-for-diabetes-management 2025-12-21T13:30:12+00:00 hourly 0.9 https://trial.medpath.com/news/d2909d5e9b275ea7/covid-19-antivirals-nirmatrelvir-ritonavir-and-molnupiravir-show-promise-in-reducing-cardiovascular-risks 2025-12-21T13:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/8fdcb55bbaa70bae/fruquintinib-sintilimab-combination-achieves-32-7-response-rate-in-advanced-pmmr-endometrial-cancer 2025-12-21T13:29:08+00:00 hourly 0.9 https://trial.medpath.com/news/763a8174ee98ee8b/sarasota-memorial-hospital-launches-gene-therapy-trials-for-bladder-cancer-treatment 2025-12-21T13:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/377d98ba527ad8bc/askbio-receives-fda-clearance-to-begin-phase-1-2-gene-therapy-trial-for-late-onset-pompe-disease 2025-12-21T05:29:40+00:00 hourly 0.9 https://trial.medpath.com/news/86845fa5f364781a/moonlake-receives-fda-clearance-for-sonelokimab-bla-submission-in-hidradenitis-suppurativa-without-additional-trials 2025-12-21T05:29:37+00:00 hourly 0.9 https://trial.medpath.com/news/3a6dcc655b206dfb/researchers-develop-novel-ethyl-cellulose-injection-system-for-cervical-dysplasia-treatment 2025-12-21T05:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/ef26890a4375cae0/novel-sflt-1-and-paclitaxel-combination-therapy-shows-synergistic-anti-tumor-effects-in-3d-breast-cancer-models 2025-12-21T05:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/70247cc5be032be2/exelixis-and-merck-launch-phase-3-litespark-033-trial-testing-novel-kidney-cancer-combination-therapy 2025-12-21T05:29:14+00:00 hourly 0.9 https://trial.medpath.com/news/9f363bafcb924528/zimbabwe-launches-groundbreaking-long-acting-hiv-prevention-injection-in-12-priority-districts 2025-12-21T05:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/c2f223133567bb9c/kalaris-therapeutics-secures-50-million-funding-to-advance-th103-for-neovascular-amd-treatment 2025-12-20T21:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/d06296b2da438c61/multistage-malaria-vaccine-achieves-54-efficacy-in-phase-2-trial-among-malian-adults 2025-12-20T21:32:48+00:00 hourly 0.9 https://trial.medpath.com/news/a05ac759e0707156/crinetics-pharmaceuticals-advances-phase-3-cah-trial-despite-leadership-transition 2025-12-20T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/d19ff4d9e872787a/fda-grants-priority-review-to-viridian-therapeutics-veligrotug-for-thyroid-eye-disease 2025-12-20T21:29:57+00:00 hourly 0.9 https://trial.medpath.com/news/0f3bdfdf218780b5/sanofi-and-regeneron-launch-real-world-studies-to-strengthen-dupilumab-s-evidence-base-across-multiple-inflammatory-conditions 2025-12-20T21:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/3448d4bf99b67c05/zydus-partners-with-myriad-genetics-to-bring-advanced-cancer-risk-assessment-tests-to-india 2025-12-20T21:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/431b9f7638e4a4d7/bristol-myers-squibb-strikes-historic-deal-with-u-s-government-to-provide-free-eliquis-to-medicaid-patients 2025-12-20T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/3670c3855ee36e28/tucatinib-approved-for-pbs-listing-offering-4500-monthly-savings-for-metastatic-breast-cancer-patients 2025-12-20T17:27:47+00:00 hourly 0.9 https://trial.medpath.com/news/5247a26ac62da56b/medtronic-files-ipo-registration-for-diabetes-business-minimed-targeting-nasdaq-listing 2025-12-20T13:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/0ef90ce1d9c279ac/cytokinetics-secures-fda-approval-for-myqorzo-breaking-bristol-myers-squibb-s-monopoly-in-hypertrophic-cardiomyopathy 2025-12-20T13:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/ee2ac03435ed4a97/gsk-partners-with-ltz-therapeutics-to-develop-novel-myeloid-cell-engager-immunotherapies 2025-12-20T09:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/654a94a98c956458/cms-proposes-international-reference-pricing-models-to-reduce-medicare-drug-costs 2025-12-20T05:29:13+00:00 hourly 0.9 https://trial.medpath.com/news/542f46eea114ef61/fda-official-s-skepticism-triggers-disc-medicine-stock-decline-amid-bitopertin-review 2025-12-20T05:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/f212d8847c827b47/sharp-therapeutics-secures-10m-funding-to-advance-gaucher-disease-treatment-toward-phase-i-trials 2025-12-20T05:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/34832b93fdcb70bb/fda-and-ema-release-joint-guidelines-for-ai-in-drug-development-as-regulatory-agencies-advance-framework-for-healthcare-ai 2025-12-20T03:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/e9bacfeaea7e485e/ai-and-precision-medicine-drive-clinical-trial-innovation-as-industry-prepares-for-2026-transformation 2025-12-20T03:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/d4a35abd7522bd7b/fda-qualifies-first-surrogate-endpoint-for-osteoporosis-drug-development-accelerating-clinical-trials 2025-12-20T02:34:45+00:00 hourly 0.9 https://trial.medpath.com/news/968b78c50a1e7310/genentech-secures-government-agreement-to-lower-drug-costs-and-expand-patient-access 2025-12-20T02:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/b1cd9dedbe336e6c/daiichi-sankyo-and-partners-advance-two-major-lung-cancer-trials-targeting-kras-g12c-and-trop2-positive-tumors 2025-12-20T00:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/26086d2622d92f56/gsk-secures-u-s-government-agreement-to-reduce-respiratory-drug-prices-by-up-to-66-for-40-million-americans 2025-12-20T00:23:40+00:00 hourly 0.9 https://trial.medpath.com/news/92f59e7e5cd6dd9a/trump-executive-order-reclassifies-cannabis-to-schedule-iii-opening-new-clinical-research-opportunities 2025-12-19T21:38:05+00:00 hourly 0.9 https://trial.medpath.com/news/0e57e75a12dadd56/nimbus-therapeutics-completes-dose-escalation-for-novel-wrn-inhibitor-ndi-219216-in-msi-h-tumors 2025-12-19T21:37:54+00:00 hourly 0.9 https://trial.medpath.com/news/cd98ff7102f55985/iba-acquires-belgian-radiochemistry-pioneer-ora-to-strengthen-nuclear-medicine-portfolio 2025-12-19T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/da99f7b4e2b53a50/nxera-pharma-regains-rights-to-phase-2-ready-schizophrenia-drug-after-boehringer-ingelheim-declines-licensing-option 2025-12-19T21:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/5cf2338c824ace09/fda-proposes-direct-contracting-model-with-venture-capital-firms-to-accelerate-healthcare-innovation 2025-12-19T21:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/5bbec8273280f43c/prophase-labs-and-advanced-biological-laboratories-announce-strategic-reverse-merger-to-create-global-diagnostics-platform 2025-12-19T21:35:16+00:00 hourly 0.9 https://trial.medpath.com/news/e441c3ff45e015b9/fda-rejection-of-low-dose-atropine-sparks-industry-petition-and-calls-for-myopia-reclassification 2025-12-19T21:34:28+00:00 hourly 0.9 https://trial.medpath.com/news/ee3e4d95690672e5/merck-announces-historic-agreement-with-u-s-government-to-expand-drug-access-and-introduce-first-oral-pcsk9-inhibitor 2025-12-19T21:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/049b2d7b122bbc27/novartis-reaches-agreement-with-us-government-to-lower-drug-prices-and-expand-manufacturing 2025-12-19T21:34:07+00:00 hourly 0.9 https://trial.medpath.com/news/bb7eb20bec73caf8/chitose-laboratory-and-fujifilm-biosciences-form-strategic-alliance-to-advance-biopharmaceutical-manufacturing 2025-12-19T21:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/ceacb878754e4e7d/bristol-myers-squibb-and-biontech-launch-phase-1-2-trial-testing-pumitamig-in-first-line-hepatocellular-carcinoma 2025-12-19T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/be0b0849ecd9108d/altamira-therapeutics-secures-china-approval-for-bentrio-nasal-spray-in-allergic-rhinitis-market 2025-12-19T21:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/3f858a1b2b2e0846/presidential-executive-order-reclassifies-cannabis-accelerating-defloria-s-phase-2-autism-drug-development 2025-12-19T21:30:33+00:00 hourly 0.9 https://trial.medpath.com/news/347186c74fd39722/repurposed-cancer-drug-sargramostim-shows-promise-in-halting-brain-cell-death-in-alzheimer-s-disease 2025-12-19T21:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/9b042577b506bc44/claros-technologies-achieves-99-99-pfas-destruction-at-commercial-scale-with-clarostechuv-platform 2025-12-19T21:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/55aac29d3fcb82b0/galectin-therapeutics-receives-fda-feedback-on-belapectin-mash-cirrhosis-program-secures-10-million-financing 2025-12-19T17:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/47bdbf0b35713a03/trump-administration-secures-major-drug-pricing-deals-with-pharmaceutical-giants-mandates-us-manufacturing-expansion 2025-12-19T17:32:34+00:00 hourly 0.9 https://trial.medpath.com/news/0d77e25a10b1ae64/catheter-precision-expands-locket-device-to-ireland-s-largest-electrophysiology-center 2025-12-19T17:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/db96211d9d4ea7c3/psyence-biomed-secures-regulatory-approval-for-nature-derived-psilocybin-in-phase-iib-cancer-adjustment-disorder-trial 2025-12-19T17:31:56+00:00 hourly 0.9 https://trial.medpath.com/news/74d58919fbfb6e17/biomarin-acquires-amicus-therapeutics-for-4-8-billion-to-expand-rare-disease-portfolio 2025-12-19T17:30:50+00:00 hourly 0.9 https://trial.medpath.com/news/540a5831d57f1d37/niowave-expands-10-year-actinium-225-supply-agreement-with-astrazeneca-for-advanced-cancer-therapies 2025-12-19T17:30:47+00:00 hourly 0.9 https://trial.medpath.com/news/9c39c82b40f7faa7/novartis-confirms-280m-radioligand-therapy-manufacturing-facility-in-denton-texas 2025-12-19T17:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/b9a245068a00bc38/bimekizumab-shows-sustained-three-year-efficacy-in-hidradenitis-suppurativa-as-treatment-landscape-expands 2025-12-19T17:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/859dd91969e36276/fda-determines-andexxa-risks-outweigh-benefits-astrazeneca-to-withdraw-anticoagulant-reversal-agent 2025-12-19T17:30:06+00:00 hourly 0.9 https://trial.medpath.com/news/f4c9ca5c072f869c/uk-government-launches-major-initiative-to-improve-brain-tumour-clinical-trial-access-through-nhs-app-integration 2025-12-19T17:28:28+00:00 hourly 0.9 https://trial.medpath.com/news/41c2f03013abff94/resveratrol-copper-combination-shows-promise-against-glioblastoma-in-early-clinical-trial 2025-12-19T17:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/6a1f817b70650df1/fda-approves-grifols-fesilty-for-congenital-fibrinogen-deficiency-treatment 2025-12-19T17:28:23+00:00 hourly 0.9 https://trial.medpath.com/news/bca376c2b29747bf/vtv-therapeutics-initiates-phase-2-trial-of-cadisegliatin-for-type-2-diabetes-in-middle-east-and-north-africa 2025-12-19T13:31:05+00:00 hourly 0.9